

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau① Pot Pub + SK
② ZPER +
Annexes

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 311/78, A61K 31/35, C07D 311/58		A1	(11) International Publication Number: WO 96/04263
			(43) International Publication Date: 15 February 1996 (15.02.96)
(21) International Application Number: PCT/US95/09804			[UA/US]; 23W374 Woodcrest Court, Naperville, IL 60540 (US). WILAYCHACK, Vilayphone [US/US]; 305 Fulton Street, Elgin, IL 60120 (US). LIN, Lin [CN/US]; Apartment #1R, 2800 South Wallace Street, Chicago, IL 60616 (US). CHEN, Wei [CN/US]; 221 Cartez Court, Naperville, IL 60563 (US). BOULANGER, William, A. [US/US]; 976 Pinehill Drive North, Schenectady, NY 12303 (US).
(22) International Filing Date: 2 August 1995 (02.08.95)			
(30) Priority Data: 08/285,655 3 August 1994 (03.08.94) US			
(60) Parent Application or Grant (63) Related by Continuation US 08/285,655 (CIP) Filed on 3 August 1994 (03.08.94)			
(71) Applicant (for all designated States except US): MEDICHEM RESEARCH, INC. [US/US]; 12305 South New Avenue, Lemont, IL 60439 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): FLAVIN, Michael, T. [US/US]; 8817 Royal Lane, Darien, IL 60561 (US). XU, Ze-Qi [CN/US]; 1150 Greensfield Drive, Naperville, IL 60563 (US). RIZZO, John, D. [US/US]; 2339 Ogden Avenue, Downers Grove, IL 60515 (US). KUCHERENKO, Alla [UA/US]; 23W374 Woodcrest Court, Naperville, IL 60540 (US). KHILEVICH, Albert [US/US]; 3844 Lizette, Glenview, IL 60025 (US). SHEINKMAN, Abram, Kivovich			(74) Agent: MIAO, Emily; Banner & Allegretti, Ltd., Ten South Wacker Drive, Chicago, IL 60606 (US).
			(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).
			SG 9700550-8 RTMP comj
Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>			
(54) Title: METHOD FOR THE PREPARATION OF (±)-CALANOLIDE A AND INTERMEDIATES THEREOF			
(57) Abstract A method of preparing (±)-calanolide A, (1), a potent HIV reverse transcriptase inhibitor, from chromene (4) is provided. Useful intermediates for preparing (±)-calanolide A and its derivatives are also provided. According to the disclosed method, chromene (4) intermediate was reacted with acetaldehyde diethyl acetal or paraldehyde in the presence of an acid catalyst with heating, or a two-step reaction including an aldol reaction with acetaldehyde and cyclization either under acidic conditions or neutral Mitsunobu conditions, to produce chromanone (7). Reduction of chromanone (7) with sodium borohydride, in the presence of cerium trichloride, produced (±)-calanolide A. A method for resolving (±)-calanolide A into its optically active forms by a chiral HPLC system or by enzymatic acylation and hydrolysis is also disclosed. Finally, a method for treating or preventing viral infections using (±)-calanolide or (-)-calanolide is provided.			

**METHOD FOR THE PREPARATION OF (±)-CALANOLIDE A
AND INTERMEDIATES THEREOF**

CROSS-REFERENCE

5 This is a continuation-in-part of co-pending U.S.
Patent Application No. 08/285,655, filed August 3, 1994.

FIELD OF THE INVENTION

10 This invention relates to a method for the
preparation of (±)-calanolide A, a potent inhibitor of HIV
reverse transcriptase, and intermediates thereof. In
particular, this invention relates to a method for large
scale production of (±)-calanolide A, chiral resolution of
(±)-calanolide A into its optically active forms, and use
of (±)-calanolide A and (-)-calanolide A for treating
viral infections.

15 **BACKGROUND OF THE INVENTION**

Human immunodeficiency virus (HIV), which is also
called human T-lymphotropic virus type III (HTLV-III),
lymphadenopathy-associated virus (LAV) or AIDS-associated
retrovirus (ARV), was first isolated in 1982 and has been
20 identified as the etiologic agent of the acquired
immunodeficiency syndrome (AIDS) and related diseases.
Since then, chemotherapy of AIDS has been one of the most
challenging scientific endeavors. So far, AZT, ddC, ddI,
and D4T have been approved by FDA and are being clinically
25 used as drugs for the treatment of AIDS and AIDS-related
complex. Although these FDA-approved drugs can extend the
life of AIDS patients and improve their quality of life,
none of these drugs are capable of curing the disease.
Bone-marrow toxicity and other side effects as well as the
30 emergence of drug-resistant viral strains limit the long-
term use of these agents.¹ On the other hand, the number
of AIDS patients worldwide has increased dramatically
within the past decade and estimates of the reported cases



THIS SHEET HAS
BEEN REPLACED

-2-

in the very near future also continue to rise dramatically. It is therefore apparent that there is a great need for other promising drugs having improved selectivity and activity to combat AIDS.¹ Several approaches including chemical synthesis, natural products screening, and biotechnology have been utilized to identify compounds targeting different stages of HIV replication for therapeutic intervention.²


Very recently, the screening program at the National Cancer Institute has discovered a class of remarkably effective anti-HIV natural products, named calanolides, from the rain forest tree *Calophyllum lanigerum*, with calanolide A, 1, being the most potent compound in the reported series.³ For example, calanolide A demonstrated 100% protection against the cytopathic effects of HIV-1, one of two distinct types of HIV, down to a concentration of 0.1 μM . This agent also halted HIV-1 replication in human T-lymphoblastic cells (CEM-SS) ($\text{EC}_{50}=0.1 \mu\text{M}/\text{IC}_{50}=20 \mu\text{M}$).³ More interestingly and importantly, calanolide A was found to be active against both the AZT-resistant G-9106 strain of HIV as well as the pyridinone-resistant A17 virus.³ Thus, the calanolides, known as HIV-1 specific reverse transcriptase inhibitors, represent novel anti-HIV chemotherapeutic agents for drug development.

The only known natural source of calanolide A, 1, was destroyed and other members of the same species did not contain the desired material.⁴ Consequently, a practical synthesis of the natural product must be developed for further study and development to be carried out on this active and promising series of compounds. Herein, we describe a method for the synthesis and resolution of ($\pm$)-calanolide A and some related compounds.

This Sheet Has Been Replaced



-3-



OBJECTS OF THE INVENTION

Accordingly, one object of the present invention is to provide a simple and practical method for preparing ($\pm$)-calanolide A, 1, from readily available starting materials and resolving the same into its optically active forms via a chiral HPLC system or enzymatic acylation and hydrolysis.

Another object of the invention is to provide useful intermediates for preparing derivatives of ($\pm$)-calanolide A.

A further object of the invention is to provide a simple and practical method for large scale preparation of ($\pm$)-calanolide A in high yields from key intermediate chromene 4.

An additional object of the invention is to provide a method for treating or preventing viral infections using ($\pm$)-calanolide A and (-)-calanolide A.

These and other objects of the invention will become apparent in view of the detailed description below.

SUMMARY OF THE INVENTION

The present invention relates to the syntheses of ($\pm$)-calanolide A and intermediates thereof, chiral resolution of ($\pm$)-calanolide and method of treating or preventing viral infections using ($\pm$)- and (-)-calanolide A.

-4-

The method of the present invention for preparing ($\pm$)-calanolide A, 1, employs chromene 4 as the key intermediate. Chromene 4 is synthesized by the sequence depicted in Scheme I. Thus, 5,7-dihydroxy-4-propylcoumarin, 2,⁵ was prepared quantitatively from ethyl butyrylacetate and phloroglucinol under Pechmann conditions.⁶ Product yield and purity were dependent on the amount of sulfuric acid used. The 8-position of 5,7-dihydroxy-4-propylcoumarin, 2, was then selectively acylated at 8-10°C by propionyl chloride and AlCl₃ in a mixture of carbon disulfide and nitrobenzene to afford 5,7-dihydroxy-8-propionyl-4-propylcoumarin, 3.


In an alternative and preferred reaction, coumarin intermediate 3 can be produced in large scale quantities and with minimal formation of undesirable 6-position acylated product and 6,8-bis-acylated product by selective acylation of 5,7-dihydroxy-4-propylcoumarin 2 with a mixture of propionic anhydride and AlCl₃ at about 70-75°C.

The chromene ring was introduced upon treatment of compound 3 with 4,4-dimethoxy-2-methylbutan-2-ol,⁸ providing 4 in 78% yield (Scheme I).


As presented in Scheme II, Robinson-Kostanecki reaction⁹ on 4 by using sodium acetate in refluxing acetic anhydride produced enone 5 in a 65% yield. This intermediate failed to afford calanolide A upon reduction with borohydride reagents such as NaBH₄/CeCl₃, NaBH₄/CuCl₂, L-selectride, 9-BBN, and DIP-chloride, and some transition metal reducing agents such as SmI₂ and [(Ph₃P)CuH]₆, presumably because attack at the pyrone and ring opening occurred preferentially. Treatment of 5 with Baker's yeast also resulted in coumarin ring cleavage while tri-*n*-butyltin hydride¹⁰ led to reduction of 5 to enol 6 in modest yield. However, treatment of 4 with acetaldehyde diethyl acetal in the presence of trifluoroacetic acid and pyridine with heating at 160°C produced chromanone 7 which can then be reduced into the final product.

-6-

Large scale production of chromanone 7 from chromene 4 can be effected under two different reactions conditions. In a one-step reaction, chromene 4 is treated with paraldehyde, instead of acetaldehyde diethylacetal, and cyclized in the presence of an acid catalyst to afford chromanone 7 in 27% yield along with 8% of the corresponding 10,11-*cis*-dimethyl derivative 7a. In a two-step reaction under aldol condensation conditions, chromene 4 was reacted with acetaldehyde to form an open-chain aldol product 7b. Aldol product 7b was then cyclized under acidic conditions such as 50% H₂SO₄ and TsOH to form both chromanone 7 and 10,11-*cis*-dimethyl derivative 7a in a 1:1 ratio with the former leading to 16% purified yield. However, under neutral Mitsunobu¹¹ conditions, 7b was reproducibly cyclized to give chromanone 7 as the predominant product and in 48% yield.



7a



7b

Finally, ($\pm$)-calanolide A was successfully formed with the desired stereochemical arrangement by subjecting chromanone 7 to Luche reduction¹² conditions (see Scheme II). ($\pm$)-Calanolide A was then resolved into optically active forms using a preparative HPLC chiral separating system¹³.

DESCRIPTION OF THE DRAWINGS

Figures 1(a) to 1(e) illustrates *in vitro* MMT assay results, as described in Example 15, using G9106 HIV viral strain which is AZT-resistant.

Figures 2(a) to 2(e) illustrates *in vitro* MMT assay results, as described in Example 15, using H112-2 HIV viral strain which was not pre-treated with AZT.

Figures 3(a) to 3(e) illustrates *in vitro* MMT assay results, as described in Example 15, using A-17 HIV viral strain which is resistant to non-nucleoside inhibitors such as TIBO and pyridinone but is sensitive to AZT.

Figures 4(a) to 4(e) illustrates *in vitro* MMT assay results, as described in Example 15, using IIIB cultivated HIV viral strain.

Figures 5(a) to 5(e) illustrates *in vitro* MMT assay results, as described in Example 15, using RF cultivated HIV viral strain.

Figure 6 is an HPLC chromatogram of (a) (+)-calanolide A on normal phase column; (b) (+)-calanolide A on a chiral HPLC column; (c) (+)-calanolide A on a chiral HPLC column and (d) (-)-calanolide A on a chiral HPLC column. The HPLC conditions are described in Example 13.

DETAILED DESCRIPTION OF THE INVENTION

All patents, patent applications, and literature references cited herein are incorporated by reference in their entirety.

According to the method of the present invention, chromene 4 is a key intermediate in the preparation of



-8-

(±)-calanolide A, 1. A preferred method for synthesizing chromene 4 from 5,7-dihydroxy-4-propylcoumarin, 2, is shown in Scheme I. According to this synthetic scheme, 5,7-dihydroxy-4-propylcoumarin, 2,⁵ was prepared quantitatively from ethyl butyrylacetate and phloroglucinol under Pechmann conditions.⁶

In conducting this reaction, a volume of a concentrated acid is added in a dropwise manner to a stirring mixture of ethyl butyrylacetate and phloroglucinol with a mole ratio ranging between about 3:1 and about 1:3, with a preferable range being about 0.9:1.0. The dropwise addition of an acid was conducted at a rate such that the temperature of the reaction mixture is maintained at a temperature ranging between about 0°C and about 120°C, preferably about 90°C.

Suitable, but not limiting, examples of concentrated acid include sulfuric acid, trifluoroacetic acid, and methanesulfonic acid. In practicing this invention, concentrated sulfuric acid is particularly preferred. As the product yield and purity appear to be dependent on the amount of concentrated sulfuric acid used, it is preferred that the amount of concentrated sulfuric acid range between about 0.5 and 10 mole, most preferably ranging between about 2 and about 3.5 mole, per mole of ethyl butyrylacetate.

The reaction mixture is then heated to a temperature ranging between about 40°C and about 150°C, preferably about 90°C, until the reaction reaches completion as determined by TLC analysis. The reaction mixture is then poured onto ice and the precipitated product is collected by filtration and dissolved in an organic solvent. Suitable, but non-limiting, examples of organic solvents include ethyl acetate, chloroform, and tetrahydrofuran. A preferred solvent is ethyl acetate. The resulting solution is then washed with brine and dried over a

-9-

suitable drying agent, e.g., sodium sulfate. The yields of this reaction are generally quantitative.

Thereafter, 5,7-dihydroxy-8-propionyl-4-propylcoumarin, 3, was prepared by selectively acylating the 8-position of 5,7-dihydroxy-4-propylcoumarin, 2, with propionyl chloride in the presence of a Lewis acid catalyst. In conducting this reaction, a solution of propionyl chloride in a suitable solvent, e.g., carbon disulfide, was added in a dropwise manner to a vigorously stirred solution of 5,7-dihydroxy-4-propylcoumarin, 2, a Lewis acid and an organic solvent cooled in an ice bath. Dropwise addition of propionyl chloride is conducted such that the temperature of the reaction mixture is maintained at a temperature ranging between 0°C and about 30°C, preferably between about 8°C and 10°C.

In practicing the invention, the amount of propionyl chloride used generally ranges between about 0.5 moles and about 6 moles, preferably ranging between about 1 mole and about 2 moles, per mole of 5,7-dihydroxy-4-propylcoumarin, 2.

Non-limiting examples of Lewis acid catalysts useful in the acylation reaction include AlCl_3 , BF_3 , SnCl_4 , ZnCl_2 , POCl_3 , and TiCl_4 . A preferred Lewis acid catalyst is AlCl_3 . The amount of Lewis acid catalyst relative to 5,7-dihydroxy-4-propylcoumarin, 2, ranges between about 0.5 and about 12 moles, preferably ranging between about 2 and about 5 moles, per mole of 5,7-dihydroxy-4-propylcoumarin, 2.

Non-limiting examples of organic solvent for use in preparing the 5,7-dihydroxy-4-propylcoumarin, 2, solution include nitrobenzene, nitromethane, chlorobenzene, or toluene and mixtures thereof. A preferred organic solvent for use in this invention is nitrobenzene.

Upon completion of the addition of propionyl chloride, the vigorously stirred reaction mixture is maintained at a temperature ranging between about 0°C and

-10-

about 120°C, preferably ranging between about 25°C and 80°C, until the reaction reaches completion as monitored by conventional means such as TLC analysis. The reaction mixture is then poured onto ice and extracted several times with a suitable solvent such as ethyl acetate, chloroform, methylene chloride, tetrahydrofuran, or a mixture of chloroform/methanol. A preferred solvent for this extraction is ethyl acetate. The extracts are then dried over a suitable drying agent, e.g., sodium sulfate, and the product may be purified by conventional means such as silica gel column chromatography.

On a small scale, the yield of 5,7-dihydroxy-8-propionyl-4-propylcoumarin 3, produced by the above described reaction is generally quantitative. However, on a larger scale, the reaction was very difficult to control and did not exclusively afford the desired product. A route developed for the synthesis of *Mammea* coumarin was initially attempted for the preparation of compound 3, but it proved too awkward and low-yielding.⁷

Since the desired 8-position acylated product 3 was always accompanied by the formation of undesired 6-position acylated product and 6,8-bis-acylated product, it was necessary to optimize the reaction conditions to minimize the formation of the undesired products and develop a more effective purification process to increase the purity and scale-up the quantities of the desired 5,7-dihydroxy-8-propionyl-4-propylcoumarin 3. An alternative and preferred route for preparing 5,7-dihydroxy-8-propionyl-4-propylcoumarin 3 in large scale quantities is then developed.

Preparation of 8-acylated coumarin 3 on a 5 gram scale as a single product (45% yield) has been achieved by adding a mixture of propionic anhydride, a Lewis acid, e.g., AlCl₃, and suitable solvent, e.g., 1,2-dichloroethane, into a vigorously stirring pre-heated mixture of coumarin, a Lewis acid, e.g., AlCl₃, and

-11-

suitable solvent, e.g., 1,2-dichloroethane, at a temperature ranging between about 40 and about 160°C, preferably ranging between about 70 and about 75°C. Dropwise addition of the propionic anhydride solution is conducted at a rate such that the temperature of the reaction mixture is maintained within the desired temperature range.

The amount of propionic anhydride used in the reaction generally ranges between about 0.5 moles and about 10 moles, preferably ranging between about 1 mole and about 2 moles, per mole of 5,7-dihydroxy-4-propylcoumarin 2.

Non-limiting examples of Lewis acid catalysts useful in the acylation reaction include AlCl_3 , BF_3 , POCl_3 , SnCl_4 , ZnCl_2 , and TiCl_4 . A preferred Lewis acid catalyst is AlCl_3 . The amount of Lewis acid catalyst relative to 5,7-dihydroxy-4-propylcoumarin, 2, ranges between about 0.5 and about 12 moles, preferably ranging between about 2 and about 4 moles, per mole of 5,7-dihydroxy-4-propylcoumarin, 2.

Suitable but nonlimiting examples of solvents for use in the invention include diglyme, nitromethane, 1,1,2, 2-tetrachloroethane, and 1,2-dichloroethane (preferred).

Upon completion of the addition of propionyl anhydride, the vigorously stirred reaction mixture is maintained at a temperature ranging between about 40°C and about 160°C, preferably ranging between about 70°C and 75°C, until the reaction reaches completion as monitored by conventional means such as TLC analysis. The workup procedure is the same as described above.

The product was purified without the use of column chromatography to afford the desired product 3. This procedure has been scaled-up to 1.7 kg of coumarin (for details see experimental section) and the yield for 8-acylated coumarin 3 was 29% after recrystallization. The yield for 8-acylated coumarin 3 may be further improved by

-12-

changing the purification processing. For example, the crude product may be recrystallized from solvent(s) other than dioxane, or a simple washing with an appropriate solvent may lead to product pure enough for the next reaction step.

Thereafter, chromene 4 was prepared by introducing the chromene ring into 5,7-dihydroxy-8-propionyl-4-propylcoumarin, 3, using 4,4-dimethoxy-2-methylbutan-2-ol. According to the method of the present invention, a solution of 5,7-dihydroxy-8-propionyl-4-propylcoumarin, 3, and 4,4-dimethoxy-2-methylbutan-2-ol in a suitable organic solvent in the presence of a base was reacted at a temperature ranging between about 40°C and about 180°C, preferably ranging between about 100°C and about 120°C, until the reaction reached completion as determined by conventional means such as TLC analysis. Water and methanol formed during the reaction were removed azeotropically via a Dean-Stark trap.

In practicing this invention, the amount of 4,4-dimethoxy-2-methylbutan-2-ol employed in the reaction generally ranges between about 0.5 and about 8 moles, preferably ranging between about 2 and about 4 moles, per mole of 5,7-dihydroxy-8-propionyl-4-propylcoumarin 3.

Suitable, but not limiting examples of organic solvents include pyridine, triethylamine, N,N-dimethylformamide (DMF), toluene, tetrahydrofuran (THF) or 1,2-dichloroethane. Suitable, but non-limiting examples of the bases include pyridine, 4-dimethylaminopyridine, triethylamine, N,N-diethylaniline, 1,5-diazabicyclo-[4,3,0]-non-5-ene (DBN), 1,8-diazabicyclo-[5,4,0]undec-7-ene (DBU), sodium carbonate and sodium bicarbonate. Pyridine was used as both base and solvent in this invention on a small scale; for scale-up, however, pyridine was used as a base and toluene was used as a solvent.

-13-

Upon completion of the reaction, the solvent is removed under reduced pressure and the reaction products is dissolved in a suitable solvent, e.g., ethyl acetate. The solution is then washed sequentially with water and brine and dried over a suitable drying agent, e.g., sodium sulfate. Thereafter, the crude chromene 4 product can be purified by conventional means such as silica gel column chromatography using 25% ethyl acetate/hexane as the elution solvent. The yields of chromene 4 generally fall with the range of about 60% and about 85%, usually resulting in about 78% yield.

Thereafter, chromanone 7 may be produced by reacting a solution of chromene 4, acetaldehyde diethylacetal, and an acid catalyst in organic solvent at a temperature ranging between about 60°C and about 140°C, preferably about 140°C, until the reaction is completed.

The amount of acetaldehyde diethylacetal used in the reaction generally ranges between about 0.5 and about 20 moles, preferably ranging between about 3 and about 5 moles, per mole of chromene 4.

Suitable, but non-limiting, examples of acid catalysts include trifluoroacetic acid, methanesulfonic acid, trifluoromethanesulfonic acid, p-tosylic acid, acetic acid, hydrofluoric acid and their pyridinium salts and mixtures thereof. A preferred acid catalyst for the use in this invention is trifluoroacetic acid. The amount of acid catalyst used generally ranges between about 2 and about 25 moles, preferably ranging between about 17 and about 22 moles, per mole of chromene 4.

Two alternative routes for preparing chromanone 7 from chromene 4 in large scale quantities were developed and which involve either a one-step reaction process (paraldehyde one-step reaction) or a two-step reaction processes (LDA/sulfuric acid process or LDA/Mitsunobu process).

(a) Paraldehyde one-step reaction:

-14-

Instead of acetaldehyde diethylacetal, paraldehyde was used as the acetaldehyde equivalent. In the presence of one or more acid catalysts such as $\text{CF}_3\text{SO}_3\text{H}$, $\text{CF}_3\text{CO}_2\text{H}$, and pyridinium p-toluenesulfonate (PPTS), chromene 4 was reacted with paraldehyde at elevated temperature in a suitable solvent to afford chromanone 7 as the major product and the corresponding 10,11-cis-dimethyl derivative 7a as a minor product.

According to this reaction, paraldehyde was added to a stirring solution of chromene 4 and an acid catalyst, e.g., PPTS, at room temperature in a suitable solvent. The resulting mixture was heated at the temperature ranging between about 40 and about 140°C, preferably ranging between about 60 and about 100°C, for a period of time ranging between about 5 and about 36 hours, preferably about 20 hours. Thereafter, $\text{CF}_3\text{CO}_2\text{H}$, an additional equivalent of PPTS and paraldehyde was added and the resulting mixture was maintained at a temperature ranging between about 40 and about 140°C, preferably ranging between about 60 and about 100°C overnight or until the reaction reached completion as determined by convention means, e.g., TLC.

The amount of paraldehyde employed per mole of chromene 4 generally ranges between about 1 and about 40 moles, preferably ranging between about 20 and about 30 moles.

Non-limiting acid catalysts include trifluoromethane sulfonic acid, trifluoroacetic acid, methanesulfonic acid, p-tosylic acid and their pyridinium salts. In practicing this invention, pyridinium p-toluenesulfonate (PPTS) is the preferred acid catalyst. The amount of acid catalyst used in the reaction ranges between about 0.5 and about 10 moles, preferably between about 1 and about 2 moles.

Representative solvents for use in the reaction include toluene, diglyme and 1,2-dichloroethane. In

-15-

practicing the invention, 1,2-dichloroethane is the preferred solvent.

Upon completion of the reaction, the reaction was neutralized with saturated bicarbonate solution and extracted with a suitable solvent, e.g., ethyl acetate. The crude product was then purified as described above. The yields of chromanone 7 from this reaction generally range between about 20 and about 60%, usually about 40%.

(b) LDA/sulfuric acid two-step reaction:

Under aldol condensation conditions, chromene 4 was reacted with acetaldehyde to form an open-chain aldol product 7b. According to the present invention, a solution of LDA in THF was added dropwise to a solution of chromene 4 in THF at a temperature ranging between about -78°C and about 0°C, preferably about -30°C and about -78°C. The amount of LDA added per mole of chromene 4 ranged between about 1 and about 4 moles, preferably ranging between about 2 and about 3 per mole of chromene 4. Dropwise addition LDA is conducted such that the reaction temperature is maintained within the desired range.

Acetaldehyde was then added dropwise to the reaction mixture in amounts ranging between about 1 and about 12 moles, preferably ranging between about 4 and about 6 moles per mole of chromene 4. Dropwise addition of acetaldehyde is conducted such that the reaction temperature is maintained within the aforementioned range. The reaction was monitored by conventional means, e.g., TLC analysis, until it reached completion.

One skilled in the art will appreciate that the aldol reaction of chromene 4 with acetaldehyde to form 7b can be carried out under conditions which employs bases other than LDA. For example, metal hydroxides such as NaOH, KOH and Ca(OH)₂, metal alkoxides such as MeONa, EtONa and t-BuOK, and amines such as pyrrolidine, piperidine, diisopropylethylamine, 1,5-diazabicyclo[4,3,0]non-5-ene

-16-

(DBN), 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU), LDA, NaNH₂ and LiHMDS as well as hydrides such as NaH and KH can all be employed for the aldol reactions.¹⁵ Also, aldol reactions can be mediated by metal complexes of Al, B, Mg, Sn, Ti, Zn and Zr compounds such as TiCl₄, (i-PrO)₃TiCl, (i-PrO)₄Ti, PhBCl₂, (n-Bu)₂BCl, BF₃, (n-Bu)₃SnCl, SnCl₄, ZnCl₂, MgBr₂, Et₃AlCl with or without chiral auxiliaries such as 1,1'-binaphthol, norephedrine sulfonate, camphanediol, diacetone glucose and dialkyl tartrate.¹⁶⁻¹⁸

Thereafter, the reaction mixture was quenched at -30°C to -10°C with saturated aqueous ammonium chloride solution and extracted with a suitable solvent, e.g., ethyl acetate. The pooled extracts were washed with brine and dried over a suitable drying agent, e.g., sodium sulfate. The yields of aldol product 7b generally range between about 40% and about 80%, usually about 70%.

It should be noted that there are two asymmetric centers in 7b. Therefore, 7b is racemic mixture of two sets of enantiomers (four optically active forms) which may be resolved by conventional resolution methods such as chromatography or fractional crystallization of suitable diastereoisomeric derivatives such as salts or esters with optically active acids (e.g., camphor-10-sulfonic acid, camphoric acid, methoxyacetic acid, or dibenzoyltartaric acid) or enzymatically catalyzed acylation or hydrolysis of the racemic esters. Also, chiral transition metal-mediated aldol reaction^{17,18} of chromene 4 with acetaldehyde may directly produce optically active one of the enantiomers of 7b. The resultant or synthetic enantiomer may then be transformed to enantioselective synthesis of (+)-calanolide A and its congeners.

The crude aldol product 7b was then cyclized under acidic conditions to form a mixture of both chromanone 7 and 10,11-cis-dimethyl derivative 7a in a 1:1 ratio. Suitable, but non-limiting, acids include one or more acids such as sulfuric acid, hydrochloric acid (aqueous or

-17-

anhydrous), trifluoroacetic acid, methanesulfonic acid, trifluoromethanesulfonic acid, p-tosylic acid, acetic acid or their mixture thereof. A preferred acid for use in the reaction is a 1:1 v/v mixture of acetic acid and 50% H₂SO₄.

5 The reaction mixture was cooled, ice water was added and the resulting mixture extracted with a suitable solvent, e.g., ethyl acetate. The pooled organic layers were washed with water, saturated bicarbonate solution and brine. The crude product was concentrated in vacuo and
10 purified by conventional means, e.g., silica gel column using a 2:3 (v/v) ethyl acetate/hexane solvent mixture. The yields of chromanone 7 from this reaction generally range between about 10% and about 40%, usually about 20% based on chromene 4.

15 One skilled in the art will also appreciate that 10,11-cis-chromanone 7A can be treated with a base under thermodynamic (equilibrium) conditions so as to afford the corresponding trans-chromanone 7. The suitable, but non-limiting, bases include metal hydroxides
20 such as NaOH, KOH and Ca(OH)₂, metal alkoxides such as MeONa, EtONa and t-BuOK, amines such as triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, N,N-diethylaniline, pyrrolidine, piperidine, 1,5-diazabicyclo[4,3,0]non-5-ene (DBN), 1,8-diazabicyclo-
25 [5,4,0]undec-7-ene (DBU), LDA and LiHMDS as well as metal hydrides such as NaH and KH.

(c) LDA/Mitsunobu two-step reaction:

In a preferred reaction, aldol product 7b may be converted to chromanone 7 as the predominant product under
30 neutral Mitsunobu reaction conditions. In this reaction, diethyl azodicarboxylate (DEAD) was added dropwise to a solution containing crude aldol product 7b and triphenylphosphine at a temperature ranging between about -10°C and about 40°C, preferably about ambient
35 temperature. The amount of DEAD used in the reaction generally ranges between about 1 mole and about 10 moles

-18-

preferably about 1 mole and about 4 moles, per mole of aldol 7b. The amount of triphenylphosphine used in the reaction generally ranged between about 1 mole and about 10 moles, preferably ranging between about 1 mole and about 4 moles, per mole of aldol 7b.

Instead of DEAD, other reagents reported in the literature can be employed such as diisopropyl azodicarboxylate (DIAD), dibutyl azodicarboxylate (DBAD), dipiperidinoazodicarboxamide, bis(N⁴-methylpiperazin-1-yl)azodicarboxamide, dimorpholinoazodicarboxamide, N,N,N',N'-tetramethylazodicarboxamide (TMAD)¹⁹. Also, in addition to triphenylphosphine, tri-n-butylphosphine,¹⁹ triethylphosphine, trimethylphosphine and tris(dimethylamino)-phosphine have been used.

Thereafter, the reaction was quenched with saturated ammonium chloride upon completion and extracted with a suitable solvent, e.g., ethyl acetate. The pooled organic layers were washed with brine, concentrated in vacuo and the crude chromanone 7 was purified by conventional means as discussed above. The yields of chromanone 7 from the LDA\Mitsunobu reaction generally range between about 30% and about 60%, usually about 50% based on chromene 4.

Suitable, but non-limiting, examples of azo compounds for the Mitsunobu reaction include diethyl azodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD), dibutyl azodicarboxylate (DBAD), dipiperidinoazodicarboxamide, bis(N⁴-methylpiperazin-1-yl)azodicarboxamide, dimorpholinoazodicarboxamide, and N,N,N',N'-tetramethylazodicarboxamide (TMAD).

Suitable, but non-limiting, examples of phosphorous derivatives for the Mitsunobu reaction include triphenylphosphine, tri-n-butylphosphine, triethylphosphine, trimethylphosphine and tris(dimethylamino)phosphine.

Finally, mild borohydride reduction of chromanone 7 in the presence of CeCl₃(H₂O), produced (±)-calanolide A

-19-

with the desired stereochemical arrangement. In conducting the reduction reaction, a solution of chromanone 7 was added dropwise into a solution of reducing agent, e.g., sodium borohydride and a metal additive, e.g., $\text{CeCl}_3(\text{H}_2\text{O})_7$, in ethanol. The rate of addition is such that the reaction mixture temperature is maintained within a range of between about -40°C and about 60°C , preferably ranging between about 10°C and about 30°C . Thereafter, the reaction mixture was stirred at a temperature ranging between about -40°C and about 60°C .

In general, the amount of metal additive, e.g., $\text{CeCl}_3(\text{H}_2\text{O})_7$, present in the reaction mixture ranged between about 0.1 and about 2 mole, preferably ranging between about 0.5 and about 1 mole, per mole of sodium borohydride. In addition, the amount of sodium reducing agent, e.g., borohydride employed in the reaction generally ranged between about 0.1 and about 12 mole, preferably ranging between about 2 and about 4 moles, per mole of chromanone 7. Suitable, but non-limiting, examples of reducing agents include NaBH_4 , LiAlH_4 , $(i\text{-Bu})_2\text{AlH}$, $(n\text{-Bu})_3\text{SnH}$, 9-BBN, $\text{Zn}(\text{BH}_4)_2$, BH_3 , DIP-chloride, selectrides and enzymes such as baker yeast. Suitable, but non-limiting, examples of metal additives include CeCl_3 , ZnCl_2 , AlCl_3 , TiCl_4 , SnCl_3 , and LnCl_3 , and their mixture with triphenylphosphine oxide. In practicing this invention, sodium borohydride as reducing agent and $\text{CeCl}_3(\text{H}_2\text{O})_7$ as metal additive are preferred.

Thereafter, the reduction mixture was diluted with water and extracted with a suitable solvent, e.g., ethyl acetate. The extract was dried over a suitable drying agent, e.g., sodium sulfate, and concentrated. The resulting residue was then purified by conventional means such as silica gel chromatography, using ethyl acetate/hexane solvent mixtures.

Thus, ($\pm$)-calanolide A, 1, was successfully prepared with the desired stereochemical arrangement by treatment

-20-

of the key intermediate chromene 4 with acetaldehyde diethyl acetal or paraldehyde in the presence of trifluoroacetic acid and pyridine or a two-step reaction including aldol reaction with acetaldehyde and cyclization either under acidic condition or neutral Mitsunobu condition to produce chromanone 7, followed by Luche reduction via chromanone 7 (see Scheme II).

An alternative route for preparing ($\pm$)-calanolide A from chromene 4 was attempted. A Robinson-Kostanecki reaction on 4 was conducted with sodium acetate in refluxing acetic anhydride and produced enone 5 in a 65-70% yield (see Scheme II). Enone 5, however, failed to afford ($\pm$)-calanolide A when being reduced with borohydride reagents and some transition metal reducing agents, presumably because attack at the pyrone and ring opening occurred preferentially. Treatment of compound 5 with Baker's yeast also resulted in coumarin ring cleavage while tri-*n*-butyltin hydride reduce enone 5 into enol 6 in a modest yield.

In another embodiment of the invention, methods for resolving ($\pm$)-calanolide A into its optically active forms, (+)-calanolide A and (-)-calanolide A, are provided. In one method, ($\pm$)-Calanolide is resolved by high performance liquid chromatography (HPLC) with organic solvent system as a mobile phase. HPLC is performed on a column packed with chiral packing material. Suitable, but not limiting, examples of chiral packing material include amylose carbamate, D-phenylglycine, L-phenylglycine, D-leucine, L-leucine, D-naphthylalanine, L-naphthylalanine, or L-naphthylleucine. These materials may be bounded, either ionically or covalently, to silica spherew which particle sizes ranging between about 5 μ m and about 20 μ m.

Suitable, but non-limiting, mobile phase includes hexane, heptane, cyclohexane, ethyl acetate, methanol, ethanol, or isopropanol and mixtures thereof. The mobile phase may be employed in isocratic, step gradient or

-21-

continuous gradient systems at flow rates generally ranging between about 0.5 mL/min. and about 50 mL/min.

Another method for resolving ($\pm$)-calanolide A into its optically active forms involves enzyme-catalyzed acylation or hydrolysis. In practicing this invention, enzyme-catalyzed acylation of ($\pm$)-calanolide A is preferred. The enzymatic resolution method employs enzymes such as lipase CC (*Candida cylindracea*), lipase AK (*Candida cylindracea*), lipase AY (*Candida cylindracea*), lipase PS (*Pseudomonas* Species), lipase AP (*Aspergillus niger*), lipase N (*Rhizopus niveus*), lipase FAP (*Rhizopus niveus*), lipase PP (Porcine Pancrease), pig (porcine) liver esterase (PLE), pig liver acetone powder (PLAP), or subtilisin. The preferred enzyme for use in the enzyme-catalyzed acylation reaction is lipase PS-13 (Sigma Corporation, St. Louis, MO, USA). Immobilized forms of the enzyme on cellite, molecular sieves, or ion exchange resin are also contemplated for use in this method. The amount of enzyme used in the reaction depends on the rate of chemical conversion desired and the activity of the enzyme.

The enzymatic acylation reaction is carried out in the presence of an acylating agent. Suitable, but not limiting, examples of acylating agents include vinyl acetate, vinyl propionate, vinyl butyrate, acetic anhydride, propionic anhydride, phthalic anhydride, acetic acid, propionic acid, hexanoic acid or octanoic acid. The enzyme reaction employs at least one mole of acylating agent per mole of ($\pm$)-calanolide A. Acylating agent can be used as a solvent in the acylation reaction or as a co-solvent with another solvent such as hexanes, chloroform, benzene and THF.

One skilled in the art will appreciate that racemic esters of calanolide A can be made by conventional esterification means and selectively hydrolyzed by the enzymes so as to produce, in high enantiomeric excess,

-22-

optically active (+)- or (-)-calanolide A in free or esterified form. The esterified calanolide A may be hydrolyzed chemically or enzymatically into the free form. Suitable, but not limiting examples of solvents for use in the enzymatic hydrolysis reaction include water, suitable aqueous buffers such as sodium phosphate buffers or alcohols such as methanol or ethanol.

In yet another embodiment of the invention, a method for treating or preventing viral infections using (+)- and (-)-calanolide is provided. (+)-Calanolide A and (-)-calanolide A have not been reported before for their anti-HIV activity. It has been discovered that (+)-calanolide A inhibits human immunodeficiency virus type 1 (HIV-1) with EC_{50} value being approximately half of that for (+)-calanolide A. Although (-) calanolide A is inactive against HIV-1, it does not exhibit synergistic effect on toxicity of (+)-calanolide A. Therefore, one skilled in the art will appreciate to directly use the synthetic (+)-calanolide A as antiviral agent, without further resolution into the optically pure (+)-calanolide A, to inhibit the growth or replication of viruses in a mammal. Examples of mammals include humans, primates, bovines, ovines, porcines, felines, canines, etc. Examples of viruses may include, but not limited to, HIV-1, HIV-2, herpes simplex virus (type 1 and 2) (HSV-1 and 2), varicella zoster virus (VZV), cytomegalovirus (CMV), papilloma virus, HTLV-1, HTLV-2, feline leukemia virus (FLV), avian sarcoma viruses such as rous sarcoma virus (RSV), hepatitis types A-E, equine infections, influenza virus, arboviruses, measles, mumps and rubella viruses. More preferably the compounds of the present invention will be used to treat a human infected with a retrovirus. Preferably the compounds of the present invention will be used to treat a human exposed or infected (i.e., in need of such treatment) with the human immunodeficiency virus, either prophylactically or therapeutically.

-23-

An advantage of certain compounds of the present invention is that they retain the ability to inhibit certain HIV RT mutants which are resistant to other non-nucleoside inhibitors such as TIBO and nevirapine or resistant to nucleoside inhibitors. This is advantageous over the current AIDS drug therapy, where biological resistance often develops to nucleoside analogs used in the inhibition of RT.

Hence the compounds of the present invention are particularly useful in the prevention or treatment of infection by the human immunodeficiency virus and also in the treatment of consequent pathological conditions associated with AIDS. Treating AIDS is defined as including, but not limited to, treating a wide range of states of HIV infection: AIDS, ARC, both symptomatic and asymptomatic, and actual or potential exposure to HIV. For example, the compounds of this invention are useful in treating infection of HIV after suspected exposure to HIV by e.g., blood transfusion, exposure to patient blood during surgery or an accidental needle stick.

Antiviral (+)-calanolide A and (-)-calanolide A may be formulated as a solution of lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use. The liquid formulation is generally a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or in buffered sodium or ammonium acetate solution. Such formulation is especially suitable for parenteral administration, but may also be used for oral administration. It may be desirable to add excipients such as polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.

-24-

Alternatively, the compounds of the present invention may be encapsulated, tableted or prepared in an emulsion (oil-in-water or water-in-oil) syrup for oral administration. Pharmaceutically acceptable solids or liquid carriers, which are generally known in the pharmaceutical formulary arts, may be added to enhance or stabilize the composition, or to facilitate preparation of the composition. Solid carriers include starch (corn or potato), lactose, calcium sulfate dihydrate, terra alba, croscarmellose sodium, magnesium stearate or stearic acid, talc, pectin, acacia, agar, gelatin, or colloidal silicon dioxide. Liquid carriers include syrup, peanut oil, olive oil, saline and water. The carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies but, preferably, will be between about 10 mg to about 1 g per dosage unit.

The dosage ranges for administration of antiviral ($\pm$)-calanolide A and (-)-calanolide A are those to produce the desired affect whereby symptoms of infection are ameliorated. For example, as used herein, a pharmaceutically effective amount for HIV infection refers to the amount administered so as to maintain an amount which suppresses or inhibits secondary infection by syncytia formation or by circulating virus throughout the period during which HIV infection is evidenced such as by presence of anti-HIV antibodies, presence of culturable virus and presence of p24 antigen in patient sera. The presence of anti-HIV antibodies can be determined through use of standard ELISA or Western blot assays for, e.g., anti-gp120, anti-gp41, anti-tat, anti-p55, anti-p17, antibodies, etc. The dosage will generally vary with age, extent of the infection, the body weight and counterindications, if any, for example, immune tolerance. The dosage will also be determined by the existence of any adverse side effects that may accompany the compounds. It

-25-

is always desirable, whenever possible, to keep adverse side effects to a minimum.

One skilled in the art can easily determine the appropriate dosage, schedule, and method of administration for the exact formulation of the composition being used in order to achieve the desired effective concentration in the individual patient. However, the dosage can vary from between about 0.001 mg/kg/day to about 50 mg/kg/day, but preferably between about 0.01 to about 1.0 mg/kg/day.

The pharmaceutical composition may contain other pharmaceuticals in conjunction with antiviral (+)-calanolide A and (-)-calanolide A, to treat (therapeutically or prophylactically) AIDS. For example, other pharmaceuticals may include, but are not limited to, other antiviral compounds (e.g., AZT, ddC, ddI, D4T, 3TC, acyclovir, gancyclovir, fluorinated nucleosides and nonnucleoside analog compounds² such as TIBO derivatives, nevirapine, α -interferon and recombinant CD4), immunostimulants (e.g., pyridinones, BHAP, HEPTs, TSAOs, α -APA various interleukins and cytokines), immunomodulators and antibiotics (e.g., antibacterial, antifungal, anti-pneumocystitis agents). Administration of the inhibitory compounds with other anti-retroviral agents that act against other HIV proteins such as protease, integrase and TAT will generally inhibit most or all replicative stages of the viral life cycle.

In addition, the compounds of the present invention are useful as tools and/or reagents to study inhibition of retroviral reverse transcriptases. For example, the instant compounds selectively inhibit HIV reverse transcriptase. Hence, the instant compounds are useful as a structure-activity relationship (SAR) tool to study, select and/or design other molecules to inhibit HIV.

The following examples are illustrative and do not serve to limit the scope of the invention as claimed.

-26-

EXPERIMENTAL

All chemical reagents and solvents referred to herein are readily available from a number of commercial sources including Aldrich Chemical Co. or Fischer Scientific. NMR spectra were run on a Hitachi 60 MHz R-1200 NMR spectrometer or a Varian VX-300 NMR spectrometer. IR spectra were obtained using a Midac M series FT-IR instrument. Mass spectral data obtained using a Finnegan MAT 90 mass spectrometer. All melting points are corrected.

EXAMPLE 1: 5,7-Dihydroxy-4-propylcoumarin⁵ (2)

Concentrated sulfuric acid (200 mL) was added into a mixture of phloroglucinol dihydrate (150 g, 0.926 mol) and ethyl butyrylacetate (161 g, 1.02 mol). The resulting mixture was stirred at 90°C for two hours whereupon it was poured onto ice. The solid product was collected by filtration, and then dissolved in ethyl acetate. The solution was washed with brine and dried over Na₂SO₄. After removal of the solvent in vacuo, the residue was triturated with hexane to provide essentially pure compound 2 (203 g) in quantitative yield, mp 233-235°C (Lit.⁵ 236-238°C). ¹H-NMR⁵ (DMSO-d₆) δ 0.95 (3H, t, J=6.9 Hz, CH₃); 1.63 (2H, apparent hextet, J=7.0 Hz, CH₂); 2.89 (2H, t, J=7.5 Hz, CH₂); 5.85 (1H, s, H₃); 6.22 (1H, d, J=2.0 Hz, H₆); 6.31 (1H, d, J=2.0 Hz, H₈); 10.27 (1H, s, OH); 10.58 (1H, s, OH); MS (EI); 220(100, M⁺); 205 (37.9, M-CH₃); 192 (65.8, M-C₂H₄); 177 (24.8, M-C₃H₇); 164 (60.9, M-CHCO₂+1); 163 (59.6 M-CHCO₂); IR (KBr): 3210 (vs and broad, OH); 1649 (vs, sh); 1617 (vs, sh); 1554 (s) cm⁻¹; Anal. calcd. for C₁₂H₂₄O₄: C, 65.45; H, 5.49; Found: C, 65.61; H, 5.44.

EXAMPLE 2: 5,7-Dihydroxy-8-propionyl-4-propylcoumarin (3)

A three-neck flask (500 mL) equipped with an efficient methanical stirrer, thermometer and addition

-27-

funnel was charged with 5,7-dihydroxy-4-propylcoumarin, 2, (25.0 g, 0.113 mol), aluminum chloride (62.1 g; 0.466 mol), and nitrobenzene (150 mL) and the mixture was stirred until a solution was obtained, which was cooled to 0°C in an ice bath. A solution of propionyl chloride (15.2 g; 0.165 mol) in carbon disulfide (50 mL) was added dropwise at such a rate that the reaction temperature was maintained at 8-10°C. Addition was completed over a period of 1 hour with vigorous stirring. The reaction was monitored by TLC using a mobile phase of 50% ethyl acetate/hexane. After three hours, an additional portion of propionyl chloride (2.10 g; 0.0227 mol) in carbon disulfide (10 mL) was added. Immediately after the TLC analysis indicated the total consumption of starting material, the reaction mixture was poured onto ice, and allowed to stand overnight. The nitrobenzene was removed by steam distillation, and the remaining solution was extracted several times with ethyl acetate. The extracts were combined and dried over Na₂SO₄. The crude product obtained by evaporation in vacuo was purified by chromatography on a silica gel column eluting with 50% ether/hexane to provide the desired propionylated coumarin 3, mp (corr) 244-246°C. ¹H-NMR (DMSO-d₆) δ 0.96 (3H, t, J=7.3 Hz, CH₃); 1.10 (3H, t, J=7.2 Hz, CH₃); 1.60 (2H, m, CH₂); 2.88 (2H, t, J= 7.7 Hz, CH₂); 3.04 (2H, q, J=7.2 Hz, CH₂); 5.95 (1H, s, H₃); 6.31 (1H, s, H₆); 11.07 (1H, s, OH); 11.50 (1H, s, OH); MS (EI): 277 (6.6, M+1); 276 (9.0, M+); 247 (100, M-C₂H₅); IR (KBr): 3239 (s and broad, OH); 1693 (s, C=O), 1625 and 1593 (s) cm⁻¹; Anal. calcd. for C₁₅H₁₆O₅: C, 65.21; H, 5.84; Found: c, 64.92; H, 5.83. The isomer assignment was made by analogy to precedent.⁷

EXAMPLE 3: 2,2-Dimethyl-5-hydroxy-6-propionyl-10-propyl-2H,8H-benzo[1,2-b:3,4-b']dipyrans-8-one (4)

A mixture of 3 (2.60 g, 9.42 mmol) and 4,4-dimethoxy-2-methylbutan-2-ol (5.54 g, 37.7 mmol) were dissolved in anhydrous pyridine (6.5 mL). The mixture was refluxed

-28-

under nitrogen for three days. After removal of the solvent in vacuo, the residue was dissolved in ethyl acetate. The ethyl acetate was washed several times with 1 N HCl and brine. It was then dried over Na₂SO₄. The crude product obtained by evaporation in vacuo was purified by silica gel column chromatography, eluting with 25% ethyl acetate/hexane to afford 2.55 g of 4 in 78.6% yield, mp 96-98°C. ¹H-NMR (CDCl₃) δ 1.05 (3H, t, J=7.3 Hz, CH₃); 1.22 (3H, t, J=7.5 Hz, CH₃); 1.53 (6H, s, 2 CH₃); 1.75 (2H, m, CH₂); 2.92 (2H, t, J=7.1 Hz, CH₂); 3.35 (2H, q, J=7.1 Hz, CH₂); 5.56 (1H, d, J=10.0 Hz, H₃); 5.98 (1H, s, H₉); 6.72 (1H, d, J=10.0 Hz, H₄); MS (EI): 343 (5.7, M+1); 342 (22.5, M+); 327 (100, M-CH₃); IR (KBr): 1728 (vs, C=O) cm⁻¹; Anal. calcd. for C₂₀H₂₂O₅: C, 70.16; H, 6.48; Found: C, 70.45; H, 6.92.

EXAMPLE 4: 10,11-Didehydro-12-oxocalanolide A (5)

A mixture of 4 (1.76 g, 5.11 mmol) and sodium acetate (0.419 g, 5.11 mmol) in acetic anhydride (12 mL) were refluxed for 10 hours whereupon the solvent was removed in vacuo. The residue was purified by silica gel column chromatography, eluting first with 25% ethyl acetate/hexane followed by 50% ethyl acetate/hexane to provide 1.16 g (62% yield) of enone 5 (6,6,10,11-tetramethyl-4-propyl-2H,6H,12H-benzo[1,2-b:3,4-b':5,6-b'']-tripyrans-2,12-dione) as a white solid, mp 209-209.5°C. ¹H-NMR (CDCl₃) δ 1.05 (3H, t, J=6.6 Hz, CH₃); 1.56 (6H, s, 2 CH₃); 1.73 (2H, m, CH₂); 1.98 (3H, s, CH₃); 2.38 (3H, s, CH₃); 2.91 (2H, t, J=7.5 Hz, CH₂); 5.69 (1H, d, J=10.0 Hz, H₇); 6.11 (1H, s, H₃); 6.71 (1H, d, J=10 Hz, H₈); MS (EI): 366 (29.6, M+); 351 (100, M-CH₃); 323 (16.5, M-C₃H₇); IR (KBr): 1734 (vs, C=O), 1657, 1640, 1610, and 1562 cm⁻¹; Anal. calcd. for C₂₂H₂₂O₅: C, 72.12; H, 6.05; Found: C, 72.14; H, 6.15.

-29-

EXAMPLE 5: 10,11-Didehydrocalanolide A (6)

A mixture of enone 5 (160 mg, 0.437 mmol) and tri-*n*-butyltin hydride (0.318 g, 1.09 mmol) in dry dioxane (2.0 mL) was refluxed under nitrogen for 12 hours. The solvent was then removed in vacuo and the residue was purified by preparative TLC using 25% ethyl acetate in hexane as the mobile phase. The product exhibited an R_f of about 0.4. Enol 6 (12-hydroxy-6,6,10,11-tetramethyl-4-propyl-2H,6H,12H-benzo[1,2-*b*:3,4-*b'*:5,6-*b''*]-tripyrans-2-one) (13.3 mg, 8%) was isolated as an oil from the plate by ethyl acetate elution. This elution may have been inefficient, and the actual yield higher, as indicated by analytical TLC of the crude product. $^1\text{H-NMR}$ (CDCl_3) δ 0.92 (3H, t, $J=6.0$ Hz, CH_3); 1.26 (3H, s, CH_3); 1.39 (3H, s, CH_3); 1.63 (2H, m, CH_2); 1.96 (3H, s, CH_3); 2.36 (3H, s, CH_3); 2.45 (2H, t, $J=6.0$ Hz, CH_2); 3.65 (1H, s, H_{12}); 5.51 (1H, d, $J=10.0$ Hz, H_7); 6.67 (1H, d, $J=10.0$ Hz, H_8); 13.25 (1H, br s, OH); MS (EI): 369 (3.8, $M+1$), 368 (4.4, $M+$), 367 (8.3, $M-1$) 366 (28.4, $M-2$), 351 (100, $M-\text{OH}$); IR(KBr): 1651 (s), 1589 (m) cm^{-1} .

EXAMPLE 6: 12-Oxocalanolide A (7)

A solution containing chromene 4 (344 mg, 1.0 mmol), acetaldehyde diethylacetal (473 mg, 4.0 mmol), trifluoroacetic acid (1.5 mL, 19.4 mmol) and anhydrous pyridine (0.7 mL) was heated at 140°C under N_2 . The reaction was monitored by TLC analysis. After 4 hours, the reaction mixture was cooled to room temperature, diluted with ethyl acetate and washed several times with 10% aqueous NaHCO_3 and brine. The organic layer was separated and dried over Na_2SO_4 . The solvent was removed in vacuo and the crude product was purified by silica gel column chromatography eluting with ethyl acetate/hexane (2:3). Chromanone 7 (10,11-*trans*-dihydro-6,6,10,11-tetramethyl-4-propyl-2H,6H,12H-benzo[1,2-*b*:3,4-*b'*:5,6-*b''*]-tripyrans-2,12-dione) (110 mg, 30% yield) was obtained m.p.

-30-

176-177° C. (Lit.⁵ 130-132° C). ¹H-NMR⁵ (CDCl₃) δ 1.02 (3H, t, J=7.5 Hz, CH₃); 1.21 (3H, d, J=6.8 Hz, CH₃); 1.51 (3H, d, J=7.0 Hz, CH₃); 1.55 (6H, 2s, 2 CH₃); 1.63 (2H, sextet, J=7.0 Hz, CH₂); 2.55 (1H, dq, J=6.9 Hz, J=11.0 Hz, H₁₁);
5 2.88 (2H, t, J=7.6 Hz, CH₂); 4.28 (1H, dq, J=6.3 Hz, J=11.0 Hz, H₁₀); 5.60 (1H, d, J=9.9 Hz, H₈); 6.04 (1H, s, H₉); 6.65 (1H, d, J=11.8 Hz, H₇); MS (CI): 369 (100, M+1).

EXAMPLE 7: (±)-Calanolide A (1):

To a solution of chromanone 7 (11 mg, 0.03 mmol) in
10 EtOH (0.4 mL) was added sodium borohydride (2.26 g, 0.06 mmol) and CeCl₃(H₂O)₇ (11.2 mg, 0.03 mmol) in EtOH (5 mL) at room temperature. After stirring for 45 minutes, the mixture was diluted with H₂O and extracted with ethyl acetate. The organic layer was dried over Na₂SO₄ and
15 concentrated. The crude product was purified by preparative TLC eluting with ethyl acetate/hexane (1:1) to afford (±)-calanolide A (1) (10.5 mg, 94%). m.p. 52-54°C, which increased to 102°C after it was dried thoroughly (Lit.⁵ 56-58°C). ¹H NMR (CDCl₃): δ 1.03 (3H, t, J=7.3Hz, CH₃) 1.15 (3H, d, J=6.8Hz, CH₃), 1.46 (3H, d, j=6.8Hz, CH₃),
20 1.47 (3H, s, CH₃), 1.51 (3H, s, CH₃), 1.66 (2H, m, CH₂), 1.93 (1H, m, H₁₁), 2.89 (2H, m, CH₂), 3.52 (1H, broad-s, OH), 3.93 (1H, m, H₁₀), 4.72 (1H, d, J=7.8Hz, H₁₂), 5.54 (1H, d, J=10.0Hz, H₇), 5.94 (1H, s, H₉), 6.62 (1H, d,
25 J=9.9Hz, H₈); MS (CI): 371 (75.4, M+1), 370 (16.1, M⁺), 353 (100, M-OH); Anal. calcd. for C₂₂H₂₅O₅: C, 71.33; H, 7.07; Found: C, 71.63; H, 7.21.

EXAMPLE 8: 5,7-Dihydroxy-4-propylcoumarin (2):

In this Example, kilogram scale preparation of
30 intermediate 2 is described. Into a stirring suspension of phloroglucinol (3574.8 g, 28.4 mol, pre-dried to constant weight) and ethyl butyrylacetate (4600 mL, 28.4 mol) was added concentrated sulfuric acid dropwise at such a rate that the internal temperature did not exceed 40°C. After

-31-

100 mL of sulfuric acid was added, the temperature rose to 70°C and the suspension turned into a yellow solid. Analysis of TLC indicated that the reaction had proceeded to completion. The reaction mixture was diluted with water (10 L) and stirred at ambient temperature overnight. The precipitated product was collected by filtration and then rinsed with water until the filtrate was neutral. A quantity of 4820 g (77% yield) of 5,7-dihydroxy-4-propylcoumarin 2 was obtained after being dried, which was identical with an authentic sample by comparison of TLC, melting point and spectroscopic data.

EXAMPLE 9: 5,7-Dihydroxy-8-propionyl-4-propylcoumarin 3

In this Example, kilogram quantities of intermediate 3 was synthesized using propionic anhydride instead of propionyl chloride. 5,7-dihydroxy-4-propyl-coumarin, 2, (1710 g, 7.77 mol) and AlCl₃ (1000 g, 7.77 mol) were mixed in 1,2-dichloroethane (9 L). The resulting orange suspension was stirred and heated to 70°C until a solution was obtained. Then, a mixture of propionic anhydride (1010 g, 7.77 mol) and AlCl₃ (2000 g, 15.54 mol) in 1,2-dichloroethane (3.4 L) was added dropwise over 3 h. The reaction was allowed to stir at 70°C for an additional hour. After being cooled down to room temperature, the reaction mixture was poured into a rapidly stirring mixture of ice water and 1N HCl. The precipitated product was taken into ethyl acetate (30 L) and the aqueous solution was extracted with the same solvent (10 L x 2). The combined extracts were successively washed with 1 N HCl (10 L), saturated aq. NaHCO₃ (10 L), and water (10 L). After being dried over MgSO₄ and concentrated *in vacuo*, a solid product (1765 g) was obtained which was washed with ethyl acetate (15 L) and recrystallized from dioxane (9.5 L) to provide 514 g of pure compound 3. From the ethyl acetate washings, an additional 100 g of compound was obtained after recrystallization from dioxane. Thus, the

-32-

combined yield for compound 3, which was identical with an authentic sample by comparison of TLC, melting point and spectroscopic data, was 29%.

5 **EXAMPLE 10: 2,2-Dimethyl-5-hydroxy-6-propionyl-10-propyl-2H,8H-benzo[1,2-b:3,4-b']dipyran-8-one (4):**

In this Example, intermediate 4 was prepared in half kilogram quantities from 3 via modification of the reaction conditions described in Example 3. A mixture of compound 3 (510.6 g, 1.85 mol) and 4,4-dimethoxy-2-methylbutan-2-ol (305.6 g, 2.06 mol) were dissolved in a
10 mixture of toluene (1.5 L) and dry pyridine (51 mL). This mixture was stirred and refluxed; water and MeOH formed during the reaction were removed azeotropically via a Dean-Stark trap. The reaction was monitored by TLC.
15 After 6 days, the reaction had proceeded to completion. The mixture was then cooled to ambient temperature and diluted with ethyl acetate (L) and 1 N HCl (1 L). The ethyl acetate solution was separated and washed with 1N HCl (500 mL) and brine (1L). After being dried over Na₂SO₄
20 and evaporated in vacuo, a quantity of 590 g (93% yield) of compound 4 was obtained which was greater than 95% pure without further purification and was compared with an authentic sample by TLC and spectroscopic data. No trace of 6-acylated or 6,8-bisacylated product was observed,
25 although a small amount of 7-monoester did form.

EXAMPLE 11: 12-Oxocalanolide A (7):

In this Example, chromanone 7 was prepared from two alternative pathways involving either a one-step reaction (procedure A) or a two-step reaction process (procedures
30 B and C).

Procedure A. Paraldehyde One-Step Reaction: To a stirring solution of chromene 4 (350 mg, 1.0 mmol) and PPTS (250 mg, 1.0 mmol) in 1,2-dichloroethane (2 mL) at ambient temperature under N₂ was added 3 mL paraldehyde (22.5
35 mmol). The resulting mixture was refluxed for 7 h. Then,

-33-

CF₃CO₂H (1 mL), an additional equivalent of PPTS and 1 mL of paraldehyde were added; the mixture was refluxed overnight. The reaction mixture was neutralized with saturated aqueous NaHCO₃ and extracted with ethyl acetate (50 mL x 3). The crude product obtained by evaporation under reduced pressure was washed with hexane. The residue was purified by column chromatography eluting with ethyl acetate/hexane (1:2) to afford 100 mg (27% yield) of chromanone 7 and 30 mg (8% yield) of 7a. Chromanone 7 (10,11-trans-dihydro-6,6,10,11-tetramethyl-4-propyl-2H,6H,12H-benzo[1,2-b:3,4-b':5,6-b"]tripyrans-2,12-dione) obtained by this method was identical with an authentic sample by comparison of TLC, HPLC and spectroscopic data.

Procedure B LDA/Sulfuric Acid Two-Step Reaction: To a stirring solution of chromene 4 (5.0 g, 14.6 mmol) in THF (75 mL) at -30°C under N₂, was added 18.3 mL (36.5 mmol) of 2 M LDA in THF. After 15 min at the same temperature, acetaldehyde (5.0 mL, 89.5 mmol) was added via syringe. The reaction was monitored by TLC analysis. After 1 h, the reaction mixture was quenched at -10°C with saturated aqueous NH₄Cl (75 mL) and extracted with ethyl acetate (125 mL x 3). The combined extracts were washed with brine (125 mL) and dried over Na₂SO₄. Removal of solvents in vacuo afforded a reddish oil of 7b (8.5 g).

The crude 7b was dissolved in acetic acid (100 mL) and then 50% H₂SO₄ (100 mL) was added with stirring. The resulting mixture was heated at 75°C for 2.5 h and then at 50°C for 4 h. TLC analysis indicated that the starting material had been consumed. The reaction mixture was determined to contain both chromanone 7 and 10,11-cis-dimethyl derivative 7a in a 1:1 ratio. After cooling to ambient temperature, the reaction mixture was poured into a mixture of ice water (500 mL) and ethyl acetate (500 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (200 mL x 3). The ethyl

-34-

acetate solutions were combined and washed with saturated aqueous NaHCO_3 and brine. After being concentrated in vacuo, the product was purified by chromatography on a silica gel column eluting with ethyl acetate/hexane (2:3) to provide 850 mg (16% yield) of chromanone 7, which was further purified by recrystallization from ethyl acetate/hexane and was identical with an authentic sample by comparison of TLC, HPLC and spectroscopic data.

Procedure C. LDA/Mitsunobu Two-Step Reaction: Into a stirring solution of THF (10 mL) containing triphenylphosphine (1.27 g, 4.80 mmol) and the crude 7b, obtained from chromene 4 (1.0 g, 2.34 mmol), 2.5 equivalents of LDA and 6.0 equivalents of acetaldehyde by the procedure described above, was added dropwise diethyl azodicarboxylate (DEAD, 0.77 mL, 4.89 mmol). The resulting reddish solution was stirred at ambient temperature under N_2 for 1 h, after which the reaction mixture was quenched with saturated aqueous NH_4Cl and extracted with ethyl acetate (50 mL x 3). The extracts were washed with brine and dried over Na_2SO_4 . After removal of solvents, the crude product was purified by column chromatography on silica gel eluting with ethyl acetate/hexane (2:3) to provide 412 mg (48% yield, based on chromene 4) of chromanone 7, the predominant product of the reaction, which was identical with an authentic sample by comparison of TLC, HPLC and spectroscopic data.

EXAMPLE 12: (±)-Calanolide A (1):

In this Example, (±)-calanolide A was prepared in multi-gram scale using the procedure described in Example 7. To a stirring solution of chromanone 7 (51.5 g, 0.14 mol) in EtOH (1.5 L) was added $\text{CeCl}_3 \cdot (\text{H}_2\text{O})_7$ (102 g, 274 mmol). The mixture was stirred for 1.5 h at room temperature under N_2 and then cooled to -30°C with an ethylene glycol/ H_2O (1:2 w/w) dry ice bath. After the

-35-

temperature was equilibrated to -30°C , NaBH_4 (21.3 g, 563 mmol) was added and stirred at the same temperature for 8.5 h, at which time the reaction was quenched with H_2O (2 L) and extracted with ethyl acetate (2 L x 3). The
5 extracts were combined, washed with brine (2 L) and dried over Na_2SO_4 . The crude product obtained by removal of solvent under reduced pressure was passed through a short silica gel column to provide 53 g of mixture which contained 68% of (+)-calanolide A, 14% of calanolide B and
10 13% of chromanone 7 as shown by HPLC. This material was subjected to further purification by preparative HPLC to afford pure (+)-calanolide A (1).

EXAMPLE 13: Chromatographic Resolution of Synthetic (+)-Calanolide A

15 The synthetic (+)-1 was resolved into enantiomers, (+)-calanolide A and (-) calanolide A, by preparative HPLC. Thus, using a normal phase silica gel HPLC column (250 mm x 4.6 mm I.D. Zorbasil, 5 μm particle size, MAC-MOD Analytical, Inc., PA, USA), the synthetic (+)-1
20 appeared as one peak with a retention time of 10.15 minutes when hexane/ethyl acetate (70:30) was used as the mobile phase at a flow rate of 1.5 mL/min and a wavelength of 290 nm was used as the uv detector setting. However, on a chiral HPLC column packed with amylose carbamate (250
25 mm x 4.6 mm I.D. Chiralpak AD, 10 μm particle size, Chiral Technologies, Inc., PA, USA), two peaks with retention times of 6.39 and 7.15 minutes in a ratio of 1:1 were observed at a flow rate of 1.5 mL/min. The mobile phase was hexane/ethanol (95:5) and the uv detector was set at
30 a wavelength of 254 nm. These two components were separated using a semi-preparative chiral HPLC column, providing the pure enantiomers of calanolide A. The chemical structures of the separated enantiomers, which were assigned based on their optical rotations and
35 compared with the reported natural product, were characterized by spectroscopic data. HPLC chromatograms

-36-

(±)-calanolide A and its optical forms are shown in Figure 6.

(+)-Calanolide A (1): mp 47-50°C (Lit.¹⁴ 45-48°C) ; $[\alpha]_D^{25} = +68.8^\circ$ (CHCl₃, c 0.7) (Lit.¹⁴ $[\alpha]_D^{25} = +66.6^\circ$ (CHCl₃, c 0.5);
5 ¹H NMR (CDCl₃) δ 1.03 (3H, t, J=7.3 Hz, CH₃), 1.15 (3H, d, J=6.8 Hz, CH₃), 1.46 (3H, d, J=6.4 Hz, CH₃), 1.47 (3H, s, CH₃), 1.51 (3H, s, CH₃), 1.66 (2H, m, CH₂), 1.93 (1H, m, H₁₁), 2.89 (2H, m, CH₂), 3.52 (1H, d, J=2.9 Hz, OH), 3.93 (1H, m, H₁₀), 4.72 (1H, dd, J=7.8 Hz, J=2.7 Hz, H₁₂), 5.54 (1H, d, J=9.9 Hz, H₇), 5.94 (1H, s, H₃), 6.62 (1H, d, J=9.9 Hz, H₉); ¹³C NMR (CDCl₃) δ 13.99 (CH₃), 15.10 (CH₃), 18.93 (CH₃), 23.26 (CH₂), 27.38 (CH₃), 28.02 (CH₃), 38.66 (CH₂), 40.42 (CH), 67.19 (CH-OH), 77.15 (CH-O), 77.67 (C-O), 104.04 (C_{4a}), 106.36 (C_{8a} and C_{12a}), 110.14 (C₃), 116.51 (C₉), 126.97 (C₇), 151.14 (C_{4b}), 153.10 (C_{8b}), 154.50 (C_{12b}), 158.88 (C₄), 160.42 (C=O); CIMS: 371 (100, M+1), 370 (23.6, M⁺), 353 (66.2, M-OH); IR: 3611 (w) and 3426 (m, broad, OH), 1734 (vs. C=O), 1643 (m), 1606 (m) and 1587 (vs) cm⁻¹; UV λ_{max} (MeOH): 204 (32,100), 228 (23,200), 283 (22,200), 325 (12,700) nm; Anal. calcd. for C₂₂H₂₆O₅·1/4H₂O: C, 70.47; H, 7.12; Found: C, 70.64; H, 7.12.

(-)-Calanolide A (1): mp 47-50°C; $[\alpha]_D^{25} = -75.6^\circ$ (CHCl₃, c 0.7) Lit.¹⁴ $[\alpha]_D^{25} = -66^\circ$ (CHCl₃, c 0.5); ¹H NMR (CDCl₃) δ 1.03 (3H, t, J=7.4 Hz, CH₃), 1.15 (3H, d, J=6.8 Hz, CH₃), 1.46 (3H, d, J=6.3 Hz, CH₃), 1.47 (3H, s, CH₃), 1.51 (3H, s, CH₃), 1.66 (2H, m, CH₂), 1.93 (1H, m, H₁₁), 2.89 (2H, m, CH₂), 3.50 (1H, d, J=2.9 Hz, OH), 3.92 (1H, m, H₁₀), 4.72 (1H, dd, J=7.8 Hz, J=2.7 Hz, H₁₂), 5.54 (1H, d, J=10.0 Hz, H₇), 5.94 (1H, s, H₃), 6.62 (1H, d, J=10.0 Hz, H₉); ¹³C NMR (CDCl₃) δ 13.99 (CH₃), 15.10 (CH₃), 18.93 (CH₃), 23.36 (CH₂), 27.38 (CH₃), 28.02 (CH₃), 38.66 (CH₂), 40.42 (CH), 67.19 (CH-OH), 77.15 (CH-O), 77.67 (C-O), 104.04 (C_{4a}), 106.36 (C_{8a} and C_{12a}), 110.14 (C₃), 116.51 (C₉), 126.97 (C₇), 151.14 (C_{4b}), 153.11 (C_{8b}), 154.50 (C_{12b}), 158.90 (C₄), 160.44 (C=O); CIMS:

-37-

371 (95.2, M+1), 370 (41.8, M⁺), 353 (100, M-OH); IR: 3443 (m, broad, OH), 1732 (vs, C=O), 1643 (m), 1606 (m) and 1584 (vs) cm⁻¹; UV λ_{max} (MeOH): 200 (20,500), 230 (19,400), 283 (22,500), 326 (12,500) nm; Anal. calcd. for (C₂₂H₂₆O₅·1/4H₂O): C, 70.47; H, 7.12; Found: C, 70.27; H, 7.21.

EXAMPLE 14: Enzymatic Resolution of (±)-Calanolide A

To a magnetically stirred suspension of (±)-Calanolide A, prepared by the method of the present invention, and vinyl butyrate (0.1 mL) in hexane (0.5 mL) at ambient temperature was added 1 mg of lipase PS-13 (*Pseudomonas Species*) (Sigma Corporations, St. Louis, MO, USA). The reaction mixture was stirred and monitored by conventional means such as TLC analysis. At 10 days, an additional 1 mg of lipase PS-13 was added. After stirring for a total of 20 days, the reaction was stopped because there was no obvious increase in ester formation. The enzyme was filtered out and the filtrate was concentrated to dryness. The residue was analyzed by HPLC (see Example 13), which showed that 21% of (-)-calanolide A had been converted into its butyrate ester form (Scheme IV). The enriched (+)-calanolide A and the butyrate ester of (-)-calanolide A can be easily separated by conventional means such as column chromatography. The enriched (+)-calanolide A may be repeatedly treated with vinyl butyrate and lipase PS-13 as described above so as to obtain high e.e. of (+)-calanolide A.

EXAMPLE 15 In Vitro evaluation of (±)- and (-)-calanolide A

This example illustrates the anti-HIV viral activity of the synthetic (±)-calanolide A and its pure enantiomers, (+)-calanolide A and (-)-calanolide A, were evaluated using the published MTT-tetrazolium method.²⁰ Retroviral agents, AZT and DDC, were used as controls for comparison purposes.

THIS SHEET HAS BEEN
REPLACED

-38-

The cells used for screening were the MT-2 and the human T4-lymphoblastoid cell line, CEM-SS, and were grown in RPMI 1640 medium supplemented with 10% fetal (v/v) heat-inactivated fetal calf serum and also containing 100 units/ml penicillin, 100 μ g/ml streptomycin, 25 mM HEPES and 20 μ g/ml gentamicin. The medium used for dilution of drugs and maintenance of cultures during the assay was the same as above. The HTLV-IIIB and HTLV-RF were propagated in CEM-SS. The appropriate amounts of the pure compounds for anti-HIV evaluations were dissolved in DMSO, then diluted in medium to the desired initial concentration. The concentrations (μ g drug/mL medium) employed were 0.0032 μ g/mL; 0.001 μ g/mL; 0.0032 μ g/mL; 0.01 μ g/mL; 0.032 μ g/mL; 0.1 μ g/mL; 0.32 μ g/mL; 1 μ g/mL; 3.2 μ g/mL; 10 μ g/mL; 32 μ g/mL; and 100 μ g/mL. Each dilution was added to plates in the amount of 100 μ l/well. Drugs were tested in triplicate wells per dilution with infected cells while in duplicate wells per dilution with uninfected cells for evaluation of cytotoxicity. On day 6 (CEM-SS cells) and day 7 (MT-2 cells) post-infection, the viable cells were measured with a tetrazolium salt, MTT (5 mg/ml), added to the test plates. A solution of 20% SDS in 0.001 N HCl is used to dissolve the MTT formazan produced. The optical density value was a function of the amount of formazan produced which was proportional to the number of viable cells. The percent inhibition of CPE per drug concentration was measured as a test over control and expressed in percent (T/C%). The data is summarized in Figures 1(a-e), 2(a-e), 3 (a-e), 4 (a-e), and 5(a-e).

Figures 1(a) to 1(e) illustrates *in vitro* MMT assay results using an isolate, G9106 HIV viral strain²¹, which is AZT-resistant. The data shows that (-)-calanolide A was relatively non-toxic at concentrations of 1 μ g/mL but exhibited very little antiviral effect. Moreover, (+)-calanolide A was effective as (+)-calanolide A in reducing

This Sheet Has Been Replaced



viral CPE. As expected, AZT had little to no effect in reducing viral CPE and enhancing cell viability.

5 Figures 2(a) to 2(e) illustrates *in vitro* MMT assay results using H112-2 HIV viral strain which was not pre-treated with AZT. As expected, the viral strain was sensitive to AZT. The data also showed that (-)-calanolide A was relatively non-toxic at concentrations of 1 ug/mL but exhibited very little antiviral effect. (+)-calanolide A was nearly as effective as (+)-calanolide A in reducing
10 viral CPE.

 Figures 3(a) to 3(e) illustrates *in vitro* MMT assay results using A-17 HIV viral strain²² which is resistant to non-nucleoside inhibitors such as TIBO and pyridinone but is sensitive to AZT. The results here parallel those
15 shown in Figures 2(a)-2(e).

 Figures 4(a)-(e) and 5(a)-(e) illustrate *in vitro* MMT assay results using lab cultivated HIV viral strains IIIB and RF, respectively. The results here also parallel those shown in Figures 2(a)-2(e).



-40-


REFERENCES:

- 1a. Brookmeyer, R., Reconstruction and Future Trends of the AIDS Epidemic in the United States, *Science*, 1991, 253, 37-42.
- 5 b. Brain, M.M.; Heyward, W.L.; Curran, J.W., The Global Epidemiology of HIV Infection and AIDS, *Annu. Rev. Microbiol.*, 1990, 44, 555-577.
- 2a. Weislow, O.S.; Kiser, R.; Fine, D.L.; Bader, J. Shoemaker, R.H.; Boyd, M.R., New Soluble-formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural Products of AIDS-Antiviral Activity. *J. Natl. Cancer Inst.*, 10 1989, 81, 577-586.
- 15 b. Mitsuya, H.; Yarchoan, R.; Broder, S., Molecular Targets for AIDS Therapy. *Science*, 1990, 249, 1533-1544.
- 20 c. Petteway, S.R., Jr.; Lambert, D.M.; Metcalf, B.W., The Chronically Infected Cells: A Target for the Treatment of HIV Infection and AIDS. *Trends Pharmacol. Sci.*, 1991, 12, 28-34.
- 25 d. Richman, D.D., Antiviral Therapy of HIV Infection, *Annu. Rev. Med.*, 1991, 42, 69-90.
- e. Haden, J.W., Immunotherapy of Human Immunodeficiency Virus Infection. *Trends Pharmacol Sci.*, 1991, 12, 107-111.
- f. Huff, J.R., HIV Protease: A Novel Chemotherapeutic Target for AIDS. *J. Med. Chem.*, 1991, 34, 2305-2314.
- 30 g. De Clercq, E., HIV Inhibitors Targeted at the Reverse Transcriptase. *AIDS Research and Human Retroviruses*, 1992, 8, 119-134.
- 35 3. Kashman, Y.; Gustafson, K.R.; Fuller, R.W.; Cardellina, J.H., II; McMahon, J.B.; Currens, M.J.; Buckheit, R.W., Jr.; Hughes, S.H.; Cragg, G.M.; Boyd, M.R., The Calanolides, a Novel HIV-Inhibitory Class of Coumarin Derivatives from the Tropical Rainforest

-41-

- Tree, *Calophyllum lanigerum*. *J. Med. Chem.* 1992, 35, 2735-2743.
4. Boyd, M.R., National Cancer Institute, Personal Communication.
- 5 5. Chenera, B.; West, M.L.; Finkelstein, J.A.; Dreyer, G.B., Total Synthesis of ($\pm$)-Calanolide A, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase. *J. Org. Chem.* 1993, 58, 5605-5606.
- 10 6. Sethna, S.; Phadke, R., The Pechmann Reaction. *Organic Reactions*, 1953, 7, 1-58 and references cited therein.
- 15 7. Crombie, L.; Jones, R.C.F.; Palmer, C.J., Synthesis of the *Mammea* Coumarin. Part 1. The Coumarin of the *Mammea* A, B, and C Series. *J. Chem. Soc., Perkin Trans. 1*, 1987, 317-331.
8. Barton, D.H.R.; Donnelly, D.M.X.; Finet, J.P.; Guiry, P.J., Total synthesis of Isorobustin. *Tetrahedron Lett.* 1990, 31, 7449-7452.
- 20 9. Kovacs, T.S.; Zarandy, M.S.; Erdohelyi, A., Cyclization of the Enol Esters of o-Acyloxyphenyl Alkyl Ketones, IV. A Kinetic Study of the Steps of the Kostanecki-Robinson Reaction. *Helv. Chim. Acta*, 1969, 52, 2636-2641.
- 25 10. Fung, N.Y.M.; de Mayo, P.; Schauble, J.H.; Weedon, A.C, Reduction by Tributyltin Hydride of Carbonyl Compounds Absorbed on Silica Gel: Selective Reduction of Aldehydes, *J. Org. Chem.* 1978, 43, 3977-3979.
- 30 11. Hughes, D.L., The Mitsunobu Reaction. *Organic Reaction*, 1992, 42, 335-656 and references cited therein.
- 35 12. Gemal, A.L.; Luche, J.L., Lanthanoids in Organic Synthesis. 6. The Reduction of α -Enones by Sodium Borohydride in the Presence of Lanthanoid Chlorides: Synthetic and Mechanistic Aspects. *J. Am. Chem. Soc.*, 1981, 103, 5454-5459.

13. Very recently, a similar work has been published in the literature; Cardellina, J. H., II; Bokesch, H. R.; McKee, T. C.; Boyd, M. R., Resolution and Comparative Anti-HIV Evaluation of the Enantiomers of Calanolides A and B. *Bioorg. Med. Chem. Lett.* 1995, 5, 1011-1014.
14. Deshpande, P. P., Tagliaferri, F.; Victory, S.F.; Yan, S.; Baker, D. C., Synthesis of Optically Active Calanolides A and B. *J. Org. Chem.* 1995, 60, 2964-2965.
15. For a review, see Nielsen, A.T.; Houlihan, W.J., The aldol Condensation. *Org. React.* 1968, 16, 1-438.
16. For reviews, see:
- (a) Mukaiyama, T., The Directed Aldol Reaction. *Org. React.* 1982, 28, 203-331.
- (b) Reetz, M.T., Chelation or Non-Chelation Control in Addition Reactions of Chiral α - and β -Alkoxy Carbonyl Compounds, *Angew. Chem. Int. Ed. Eng.* 1984, 23, 556-569.
- (c) Shibata, I.; Baba, A., Organotin Enolates in Organic Synthesis. *Org. Prep. Proc. Int.* 1994, 26, 85-100.
17. For a review on chiral titanium complexes, see Duthaler, R.O.; Hafner, A., Chiral Titanium Complexes for Enantioselective Addition of Nucleophiles to Carbonyl Groups. *Chem. Rev.*, 1992, 92, 807-832 and reference cited therein.
18. For a review on chiral boron complexes, see Paterson, L.; Goodman, J.M.; M., Aldol Reactions in Polypropinonate Synthesis: High π -Face Selectivity of Enol Borinates from α -Chiral Methyl and Ethyl Ketones under Substrate Control. *Tetrahedron Lett.* 1989, 30, 7121-7124 and references cited therein.
19. Tsunoda, T.; Yamamiya, Y.; Kawamura, Y.; Ito, S., Mitsunobu Acylation of Sterically Congested Secondary Alcohols by N,N,N',N'-Tetramethylazodicarboxamide-



-43-

- Tributylphosphine Reagents. *Tetrahedron Lett.* 1995, 36, 2529-2530.
20. Gulakowski, R.J.; McMahon, J.B.; Staley, P.G.; Moran, R.A.; Boyd, M.R., A Semiautomated Multiparameter Approach for Anti-HIV Drug Screening, *J. Virol. Methods*, 1991, 33, 87-100.
- 5
21. Larder, B.A.; Darby, G.; Richman, D.D., HIV with reduced Sensitivity to Zidovudine (AZT) isolated during Prolonged Therapy. *Science*, 1989, 243, 1731-1734.
- 10
22. Nunberg, J.H.; Schleif, W.A.; Boots, E.J.; O'Brien, J.A.; Quintero, J.C.; Hoffman, J.M.; Emini, E.A.; Goldman, M.E., Viral Resistance to Human Immunodeficiency Virus Type 1-specific Pyridinone Reverse Transcriptase, *J. Virol.*, 1991, 65, 4887-4892.
- 15

This Sheet Has Been Replaced



THIS SHEET HAS BEEN
REPLACED

-44-

This Sheet Has Been Replaced

WHAT IS CLAIMED IS:

1. A method for the preparation of ($\pm$)-calanolide A comprising the steps of:

5 (a) condensing ethyl butyrylacetate and phloroglucinol in the presence of an acid catalyst to form 5,7-dihydroxy-4-propylcoumarin;

(b) acylating 5,7-dihydroxy-4-propylcoumarin with propionyl chloride in the presence of a Lewis acid to form 5,7-dihydroxy-8-propionyl-4-propylcoumarin;

10 (c) reacting 5,7-dihydroxy-8-propionyl-4-propylcoumarin with 4,4-dimethoxy-2-methylbutan-2-ol so as to produce 5-hydroxy-2,2-dimethyl-6-propionyl-10-propyl-2H,8H-benzo[1,2-b:3,4-b']-dipyran-8-one;

15 (d) reacting 5-hydroxy-2,2-dimethyl-6-propionyl-10-propyl-2H,8H-benzo[1,2-b:3,4-b']-dipyran-8-one with acetaldehyde diethyl acetal in the presence of an acid catalyst to form 12-oxocalanolide A; and

(e) reducing 12-oxocalanolide A so as to form ($\pm$)-calanolide A.

20 2. The method of claim 1, wherein the acid catalyst comprises sulfuric acid, trifluoroacetic acid, or methanesulfonic acid.

25 3. The method of claim 1, wherein step (e) is performed with a reducing agent comprising sodium borohydride, zinc borohydride, borane, or selectrides in the presence of a metal additive comprising $\text{CeCl}_3(\text{H}_2\text{O})_7$, ZnCl_2 , AlCl_3 , TiCl_4 , SnCl_3 , or LnCl_3 , or their mixture with triphenylphosphine oxide.

30 4. The method of claim 1, wherein step (a) acid catalyst comprises sulfuric acid, trifluoroacetic acid, methanesulfonic acid, or trifluoromethanesulfonic acid.



* C L M S *



-45-

5. The method of claim 1, wherein step (b) Lewis acid comprises AlCl_3 , ZnCl_2 , TiCl_4 , BF_3 , POCl_3 , or SnCl_4 .

6. 5-Hydroxy-2,2-dimethyl-6-propionyl-10-propyl-2H,8H-benzo[1,2-b:3,4-b']-dipyrans-8-one.

5 7. 5,7-Dihydroxy-8-propionyl-4-propylcoumarin.

8 A method for the preparation of ($\pm$)-calanolide A comprising steps of:

(a) reacting chromene 4 with paraldehyde in the presence of an acid catalyst to form chromanone 7;

10 (b) reducing chromanone 7 so as to form ($\pm$)-calanolide A.

9. The method of claim 8, wherein step (a) acid catalyst comprises trifluoroacetic acid, trifluoromethanesulfonic acid, methanesulfonic acid, or
15 pyridinium salts thereof.

10. The method of claim 8, wherein step (b) is performed with a reducing agent comprising sodium borohydride, zinc borohydride, borane or selectrides in the presence of a metal additive comprising $\text{CeCl}_3(\text{H}_2\text{O})_7$,
20 ZnCl_2 , AlCl_3 , TiCl_4 , SnCl_3 , LnCl_3 , or mixtures thereof with triphenylphosphine oxide.

11. A method for the preparation of chromene 4 comprising the steps of:

25 (a) acylating 5,7-dihydroxy-4-propylcoumarin with propionic anhydride in the presence of a Lewis acid so as to produce 5,7-dihydroxy-8-propionyl-4-propylcoumarin;

(b) reacting said 5,7-dihydroxy-8-propionyl-4-propylcoumarin with 4,4-dimethoxy-2-methylbutan-2-ol in the presence of a base so as to produce chromene 4.





-46-

THIS

12. The method of claim 11, wherein step (a) Lewis acid comprises AlCl_3 , ZnCl_2 , TiCl_4 , BF_3 , POCl_3 , or SnCl_4 .

13. The method of claim 11, wherein step (b) base comprises pyridine, 4-dimethylaminopyridine, triethylamine, N,N-diethylaniline, 1,5-diazabicyclo[4,3,0]non-5-ene (DBN), 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU), sodium carbonate or sodium bicarbonate.

14. The method of claim 11, wherein step (b) is conducted in the presence of a solvent comprising N,N-dimethylformamide (DMF), toluene, 1,2-dichloroethane and THF.

15. A method for preparation of aldol product 7b comprising reacting chromene 4 with acetaldehyde in the presence of a base or metal complex so as to produce said aldol product 7b.

16. The method of claim 15, wherein the base comprises a metal hydroxide, a metal alkoxide, a metal hydride, a metal amide, an amine, or LiHMDS.

17. The method of claim 15, wherein the metal complex comprises TiCl_4 , $(i\text{-PrO})_3\text{TiCl}$, $(i\text{-PrO})_4\text{Ti}$, PhBCl_2 , $(n\text{-Bu})_2\text{BCl}$, BF_3 , $(n\text{-Bu})_3\text{SnCl}$, SnCl_4 , ZnCl_2 , MgBr_2 , or Et_2AlCl .

18. The method of claim 17, further comprising a chiral auxiliary comprising 1,1'-binaphthol, norephedrine sulfonate, camphanediol, diacetone glucose or dialkyl tartrate.

19. A method for preparation of chromanone 7 comprising cyclization of aldol product 7b in the presence



* C L M S *



-47-

of an acid or in the presence of an azo compound and a phosphorus derivative.

20. The method of claim 19, wherein the acid comprises sulfuric acid, hydrochloric acid, trifluoroacetic acid, methanesulfonic acid, trifluoromethanesulfonic acid, p-tosylic acid, acetic acid or mixtures thereof.

21. The method of claim 19, wherein the azo compound comprises diethyl azodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD), dibutyl azodicarboxylate (DBAD), dipiperidinoazodicarboxamide, bis(N⁴-methylpiperazin-1-yl)azodicarboxamide, dimorpholinoazodicarboxamide, or N,N,N',N'-tetramethylazodicarboxamide (TMAD).

22. The method of claim 19, wherein the phosphorous derivative comprises triphenylphosphine, tri-n-butylphosphine, triethylphosphine, trimethylphosphine and tris(dimethylamino)phosphine.

23. A method of preparation of chromanone 7 comprising treating cis-chromanone 7a with a base so as to form chromane 7.

24. The method of claim 23, wherein the base comprises a metal hydroxide, a metal alkoxide, a metal hydride, a metal amide, an amine, or LiHMDS.

25. A method of chiral resolution of (±)-calanolide A into its optically active forms, (+)-calanolide A and (-)-calanolide A, comprising passing (±)-calanolide A through a column comprising a chiral solid phase using an organic solvent system as a mobile phase.



* C L M S *



-48-

THIS SHEET

26. The method of claim 25, wherein said chiral solid phase comprises amylose carbamate, D-phenylglycine, L-phenylglycine, D-leucine, L-leucine, D-naphthylalanine, L-naphthylalanine, or L-naphthylleucine.

5 27. The method of claim 25, wherein the column comprises an HPLC column.

28. The method of claim 25, wherein the chiral solid phase comprises amylose carbamate.

10 29. The method of claim 25, wherein a mobile phase comprising hexane, heptane, cyclohexane, ethyl acetate, methanol, ethanol, isopropanol or mixtures thereof.

30. The method of claim 29, wherein the mobile phase comprises a mixture of hexane and ethyl acetate.

15 31. A method for the chiral resolution ($\pm$)-calanolide A comprising the steps of:

(a) contacting ($\pm$)-calanolide A with an enzyme and an acylating agent to as to form a diastereomeric mixture of esterified and unesterified calanolide A; and

20 (b) separating out the esterified calanolide A from the mixture.

25 32. The method of claim 31, wherein the enzyme comprises lipase CC (Candida cylindracea), lipase AK (Candida cylindracea), lipase AY (Candida cylindracea), lipase PS (Pseudomonas species), lipase AP (Aspergillus niger), lipase N (Rhizopus niveus), lipase FAP (Rhizopus niveus), lipase PP (Porcine Pancreas), Pig (porcine) Liver Esterase (PLE), Pig Liver Acetone Powder (PLAP), or subtilisin.



* C L M S *

THIS SHEET HAS BEEN
REPLACED

-49-

33. The method of claim 32, wherein the enzyme is immobilized on cellite, molecular sieves, or ion exchange resin.

5 34. The method of claim 31, wherein the acylating agent comprises vinyl acetate, vinyl propionate, vinyl butyrate, acetic anhydride, propionic anhydride, phthalic anhydride, acetic acid, propionic acid, hexanoic acid or octanoic acid.

10 35. 5-Hydroxy-2,2-dimethyl-6-(1-methyl-2-hydroxybutyro)-10-propyl-2H,8H-benzo[1,2-b:3,4-b']dipyrans-8-one.

36. 10,11-cis-Dihydro-6,6,10,11,tetramethyl-4-propyl-2H,6H,12H-benzo[1,2-b:3,4-b':5,6-b'']-tripyrans-2,12-dione.

15 37. (-)-Calanolide A.

38. An antiviral composition which comprises an antiviral effective, non-toxic amount of ($\pm$)-calanolide A or (-)-calanolide A and a pharmaceutically acceptable carrier.

20 39. The composition of claim 39, which further comprises an antiviral effective amount of at least one additional antiviral compound.

40. The composition of claim 39, wherein said antiviral compound comprises AZT or DDC.

25 41. A method of preventing or treating a viral infection in a mammal comprises administering to a mammal an antiviral effective, non-toxic amount of ($\pm$)-calanolide A or (-)-calanolide A.



* C L M S *

THIS SHEET HAS BEEN
REPLACED

-50-

42. The method of claim 41, which further comprises co-administering an antiviral effective amount of at least one additional antiviral compound.

5 43. The method of claim 42, wherein said antiviral compound comprises AZT or DDC.

44. The method of claim 37, wherein said viral infection is by retrovirus.

45. The method of claim 44, wherein said retrovirus is a human immunodeficiency virus (HIV).

10 46. The method of claim 41, wherein the mammal is a human.

This Sheet Has Been Replaced



* C L M S *


SUBSTITUTE SHEET (RULE 26)

1/24

THIS SHEET HAS BEEN REPLACED

FIG. 1A

**SUMMARY GRAPH
DDC vs. HIV**




SUBSTITUTE SHEET (RULE 26)

This Sheet Has Been Replaced



FIG. 1B

**SUMMARY GRAPH
AZT vs. HIV**




THIS SHEET HAS BEEN REPLACED

3/24

THIS SHEET HAS BEEN REPLACED

FIG. 1C

**SUMMARY GRAPH
(-) CALANOLIDE A vs. HIV**



SUBSTITUTE SHEET (RULE 26)

This Sheet Has Been Replaced




4/24

THIS SHEET HAS BEEN REPLACED

FIG. 1D

SUMMARY GRAPH
(+) CALANOLIDE A vs. HIV



SUBSTITUTE SHEET (RULE 26)


This Sheet Has Been Replaced



5/24

FIG. 1E

**SUMMARY GRAPH
RACEMIC CALANOLIDE A vs. HIV**



SUBSTITUTE SHEET (RULE 26)


This Sheet Has Been Replaced



FIG. 2A

SUMMARY GRAPH

DDC vs. HIV




SUBSTITUTE SHEET (RULE 26)

This Sheet Has Been Replaced



FIG. 2B

SUMMARY GRAPH
AZT vs. HIV




THIS SHEET HAS BEEN REPLACED



8/24

FIG. 2C

SUMMARY GRAPH
(-) CALANOLIDE A vs. HIV



This Sheet Has Been Replaced



SUBSTITUTE SHEET (RULE 26)


9/24

THIS SHEET HAS BEEN REPLACED

FIG. 2D

SUMMARY GRAPH

(+) CALANOLIDE A vs. HIV




SUBSTITUTE SHEET (RULE 26)

This Sheet Has Been Replaced



FIG. 2E

**SUMMARY GRAPH
RACEMIC CALANOLIDE A vs. HIV**



THIS SHEET HAS BEEN REPLACED


This Sheet Has Been Replaced



11/24

FIG. 3A

**SUMMARY GRAPH
DDC vs. HIV**



THIS SHEET HAS BEEN REPLACED

SUBSTITUTE SHEET (RULE 26)

This Sheet Has Been Replaced



FIG. 3B

**SUMMARY GRAPH
AZT vs. HIV**





FIG. 3C

SUMMARY GRAPH
(-) CALANOLIDE A vs. HIV



THIS SHEET HAS BEEN REPLACED


This Sheet Has Been Replaced



14/24

FIG. 3D


SUMMARY GRAPH
(+) CALANOLIDE A vs. HIV



15/24

FIG. 3E

SUMMARY GRAPH
RACEMIC CALANOLIDE A vs. HIV



THIS SHEET HAS BEEN REPLACED




16/24

THIS SHEET HAS BEEN REPLACED

FIG. 4A

**SUMMARY GRAPH
AZT vs. HIV**



SUBSTITUTE SHEET (RULE 26)

This Sheet Has Been Replaced



17/24

FIG. 4B

SUMMARY GRAPH

DDC vs. HIV





FIG. 4C

**SUMMARY GRAPH
RACEMIC CALANOLIDE A vs. HIV**



THIS SHEET HAS BEEN
REPLACED

This Sheet Has Been Replaced




SUBSTITUTE SHEET (RULE 26)

19/24

FIG. 4D

**SUMMARY GRAPH
(+) CALANOLIDE A vs. HIV**



THIS SHEET HAS BEEN REPLACED

(%) OF
CONTROL
CELL
VIABILITY

SUBSTITUTE SHEET (RULE 26)

This Sheet Has Been Replaced




20/24

THIS SHEET HAS BEEN REPLACED

FIG. 5A

SUMMARY GRAPH
AZT vs. HIV




SUBSTITUTE SHEET (RULE 26)

This Sheet Has Been Replaced



FIG. 5B

**SUMMARY GRAPH
DDC vs. HIV**




THIS SHEET HAS BEEN REPLACED



22/24

FIG. 5C

**SUMMARY GRAPH
RACEMIC CALANOLIDE A vs. HIV**



THIS SHEET HAS BEEN REPLACED

SUBSTITUTE SHEET (RULE 26)

This Sheet Has Been Replaced




23/24

THIS SHEET HAS BEEN REPLACED

FIG. 5D

**SUMMARY GRAPH
(+) CALANOLIDE A vs. HIV**



SUBSTITUTE SHEET (RULE 26)

This Sheet Has Been Replaced



THIS SHEET HAS BEEN
REPLACED

24/24

CALANOLIDE B

(±) - CALANOLIDE A




FIG. 6A




FIG. 6B




FIG. 6C






FIG. 6D



-5-
SCHEME I



SCHEME II



This is the replacement sheet

Date: 28 FEB 1997

AMENDED SHEET

Finally, ($\pm$)-calanolide A was successfully formed with the desired stereochemical arrangement by subjecting chromanone 7 to Luche reduction¹² conditions (see Scheme II). ($\pm$)-Calanolide A was then resolved into optically active forms using a preparative HPLC chiral separating system¹³.

DESCRIPTION OF THE DRAWINGS

Figures 1(a) to (e) illustrates in vitro MMT assay results, as described in Example 15, using G9106 HIV viral strain which is AZT-resistant.

Figures 2(a) to (e) illustrates in vitro MMT assay results, as described in Example 15, using H112-2 HIV viral strain which was not pre-treated with AZT.

Figures 3(a) to (e) illustrates in vitro MMT assay results, as described in Example 15, using A-17 HIV viral strain which is resistant to non-nucleoside inhibitors such as TIBO and pyridinone, but is sensitive to AZT.

Figures 4(a) to (d) illustrates in vitro MMT assay results, as described in Example 15, using IIB cultivated HIV viral strain.

Figures 5(a) to (d) illustrates in vitro MMT assay results, as described in Example 15, using RF cultivated HIV viral strain.

Figures 6(a) to (d) are HPLC chromatograms of (Fig. 6(a)) (+)-calanolide A on normal phase column; (Fig. 6(b)) (+)-calanolide A on a chiral HPLC column; (Fig. 6(c)) (+)-calanolide A on a chiral HPLC column and (Fig. 6(d)) (-)-calanolide A on a chiral HPLC column. The HPLC conditions are described in Example 13.

DETAILED DESCRIPTION OF THE INVENTION

All patents, patent applications, and literature references cited herein are incorporated by reference in their entirety.

According to the method of the present invention, chromene 4 is a key intermediate in the preparation of

This is the replacement sheet

AMENDED SHEET

Date: 28 FEB 1997

The cells used for screening were the MT-2 and the human T4-lymphoblastoid cell line, CEM-SS, and were grown in RPMI 1640 medium supplemented with 10% fetal (v/v) heat-inactivated fetal calf serum and also containing 100 units/ml penicillin, 100 µg/ml streptomycin, 25 mM HEPES and 20 µg/ml gentamicin. The medium used for dilution of drugs and maintenance of cultures during the assay was the same as above. The HTLV-IIIB and HTLV-RF were propagated in CEM-SS. The appropriate amounts of the pure compounds for anti-HIV evaluations were dissolved in DMSO, then diluted in medium to the desired initial concentration. The concentrations (ug drug/mL medium) employed were 0.0032 ug/mL; 0.001 ug/mL; 0.0032 ug/mL; 0.01 ug/mL; 0.032 ug/mL; 0.1 ug/mL; 0.32 ug/mL; 1 ug/mL; 3.2 ug/mL; 10 ug/mL; 32 ug/mL; and 100 ug/mL. Each dilution was added to plates in the amount of 100 µl/well. Drugs were tested in triplicate wells per dilution with infected cells while in duplicate wells per dilution with uninfected cells for evaluation of cytotoxicity. On day 6 (CEM-SS cells) and day 7 (MT-2 cells) post-infection, the viable cells were measured with a tetrazolium salt, MTT (5 mg/ml), added to the test plates. A solution of 20% SDS in 0.001 N HCl is used to dissolve the MTT formazan produced. The optical density value was a function of the amount of formazan produced which was proportional to the number of viable cells. The percent inhibition of CPE per drug concentration was measured as a test over control and expressed in percent (T/C%). The data is summarized in Figures 1(a-e), 2(a-e), 3 (a-e), 4 (a-d), and 5(a-d).

Figures 1(a) to 1(e) illustrates in vitro MTT assay results using an isolate, G9106 HIV viral strain²¹, which is AZT-resistant. The data shows that (-)-calanolide A was relatively non-toxic at concentrations of 1 ug/mL but exhibited very little antiviral effect. Moreover, (±)-calanolide A was effective as (+)-calanolide A in reducing

This is the replacement sheet

AMENDED SHEET

Date: 28 FEB 1997

-39-

viral CPE. As expected, AZT had little to no effect in reducing viral CPE and enhancing cell viability.

5 Figures 2(a) to 2(e) illustrates in vitro MMT assay results using H112-2 HIV viral strain which was not pre-treated with AZT. As expected, the viral strain was sensitive to AZT. The data also showed that (-)-calanolide A was relatively non-toxic at concentrations of 1 ug/mL but exhibited very little antiviral effect. (+)-calanolide A was nearly as effective as (+)-calanolide A in reducing
10 viral CPE.

15 Figures 3(a) to 3(e) illustrates in vitro MMT assay results using A-17 HIV viral strain²² which is resistant to to non-nucleoside inhibitors such as TIBO and pyridinone but is sensitive to AZT. The results here parallel those shown in Figures 2(a)-2(e).

 Figures 4(a)-(d) and 5(a)-(d) illustrate in vitro MMT assay results using lab cultivated HIV viral strains IIB and RF, respectively. The results here also parallel those shown in Figures 2(a)-2(e).

This is the replacement sheet

AMENDED SHEET

Date: 28 FEB 1997

**METHOD FOR THE PREPARATION OF (±)-CALANOLIDE A
AND INTERMEDIATES THEREOF**

CROSS-REFERENCE

5 This is a continuation-in-part of co-pending U.S.
Patent Application No. 08/285,655, filed August 3, 1994,
now U.S. Patent No. 5,489,697, granted February 6, 1996.

FIELD OF THE INVENTION

10 This invention relates to a method for the
preparation of (±)-calanolide A, a potent inhibitor of HIV
reverse transcriptase, and intermediates thereof. In
particular, this invention relates to a method for large
scale production of (±)-calanolide A, chiral resolution of
(±)-calanolide A into its optically active forms, and use
of (±)-calanolide A and (-)-calanolide A for treating
15 viral infections.

BACKGROUND OF THE INVENTION

Human immunodeficiency virus (HIV), which is also
called human T-lymphotropic virus type III (HTLV-III),
lymphadenopathy-associated virus (LAV) or AIDS-associated
20 retrovirus (ARV), was first isolated in 1982 and has been
identified as the etiologic agent of the acquired
immunodeficiency syndrome (AIDS) and related diseases.
Since then, chemotherapy of AIDS has been one of the most
challenging scientific endeavors. So far, AZT, ddC, ddI,
25 and D4T have been approved by FDA and are being clinically
used as drugs for the treatment of AIDS and AIDS-related
complex. Although these FDA-approved drugs can extend the
life of AIDS patients and improve their quality of life,
none of these drugs are capable of curing the disease.
30 Bone-marrow toxicity and other side effects as well as the
emergence of drug-resistant viral strains limit the long-
term use of these agents.¹ On the other hand, the number
of AIDS patients worldwide has increased dramatically
within the past decade and estimates of the reported cases

AMENDED SHEET

This is the replacement sheet

28 FEB 1997

in the very near future also continue to rise dramatically. It is therefore apparent that there is a great need for other promising drugs having improved selectivity and activity to combat AIDS.¹ Several
5 approaches including chemical synthesis, natural products screening, and biotechnology have been utilized to identify compounds targeting different stages of HIV replication for therapeutic intervention.²

Very recently, the screening program at the National
10 Cancer Institute has discovered a class of remarkably effective anti-HIV natural products, named calanolides, from the rain forest tree *Calophyllum lanigerum*, with calanolide A, 1, being the most potent compound in the reported series.³ For example, calanolide A demonstrated
15 100% protection against the cytopathic effects of HIV-1, one of two distinct types of HIV, down to a concentration of 0.1 μ M. This agent also halted HIV-1 replication in human T-lymphoblastic cells (CEM-SS) ($EC_{50}=0.1 \mu$ M/ $IC_{50}=20 \mu$ M).³ More interestingly and importantly, calanolide A was
20 found to be active against both the AZT-resistant G-9106 strain of HIV as well as the pyridinone-resistant A17 virus.³ Thus, the calanolides, known as HIV-1 specific reverse transcriptase inhibitors, represent novel anti-HIV chemotherapeutic agents for drug development.

25 The only known natural source of calanolide A, 1, was destroyed and other members of the same species did not contain the desired material.⁴ Consequently, a practical synthesis of the natural product must be developed for further study and development to be carried out on this
30 active and promising series of compounds. Herein, we describe a method for the synthesis and resolution of ($\pm$)-calanolide A and some related compounds.

This is the replacement sheet

Date: 28 FEB 1997

AMENDED SHEET

- Tributylphosphine Reagents. *Tetrahedron Lett.* 1995, 36, 2529-2530.
20. Gulakowski, R.J.; McMahon, J.B.; Staley, P.G.; Moran, R.A.; Boyd, M.R., A Semiautomated Multiparameter Approach for Anti-HIV Drug Screening, *J. Virol. Methods*, 1991, 33, 87-100.
21. Larder, B.A.; Darby, G.; Richman, D.D., HIV with reduced Sensitivity to Zidovudine (AZT) isolated during Prolonged Therapy. *Science*, 1989, 243, 1731-1734.
22. Nunberg, J.H.; Schleif, W.A.; Boots, E.J.; O'Brien, J.A.; Quintero, J.C.; Hoffman, J.M.; Emini, E.A.; Goldman, M.E., Viral Resistance to Human Immunodeficiency Virus Type 1-specific Pyridinone Reverse Transriptase, *J.Virol.*, 1991, 65, 4887-4892.
23. WO 94/14789, published July 7, 1994 (Smithkline Beecham Corporation) relates to optically pure inophyllum and calophyllolide compounds extracted from leaves and twigs of *C. inophyllum* as well as procedures for synthesizing inophyllum, calanolide and other related coumarin derivatives.
24. Crombie, L.; Jones, Raymond C.F.; Palmer, Christopher J., Synthesis of Mammehins and Surangin A, *Tetrahedron Letters*, 1995, 26, 2929-2932 relates to general synthetic procedures for preparing 4-alkyl and 4-aryl mammea coumarins.
25. Kashman, Y.; Gustafson, K.R.; Fuller, R.W.; Cardellina, J.H., II; McMahon, J.B.; Currens, M.J.; Buckheit, R.W., Jr.; Hughes, S.H.; Cragg, G.M.; Boyd, M.R., The Calanolides, a Novel HIV-Inhibitory Class of Coumarin Derivatives from the Tropical Rainforest Tree, *Calophyllum lanigerum*, *J. Med. Chem.*, 1992, 35, 2735-2743 relates to eight enantiomers of various calanolides extracted from fruit and twigs of *Calophyllum langerium* and chemical and biological characterization of the same. Enantiomerically pure

This is the replacement sheet

Date: 28 FEB 1997

AMENDED SHEET

calanolides were tested for anti-HIV-1 reverse transcriptase activity.

- 5 26. Games, D.E., Identification of 4-Phenyl and 4-Alkylcoumarins in *Mammea Americana* L., *Mammea Africana* G. Don and *Calophyllum Inophyllum* by Gas Chromatography - Mass Spectrometry, *Tetrahedron Letters*, 1972, 341, 3187-3190 relates to identification of 4-phenyl and 4-alkylcoumarins in *Mammea americana* L. extracts by GC\MS.
- 10 27. Crombie, L. and Games, D.E. Isolation and Structure of *Mammea* B/BA, B/BB, B/BC and C/BB; A Group of 4-n-Propyl- and 4-n-Amyl-Coumarin Extractives of *Mammea americana* L., *Tetrahedron Letters*, 2, 151-156 relates to isolation of 4-alkyl mammea coumarins from *Mammea americana* L. extracts.
- 15 28. Palmer, C.J.; Josephs, J.L.; Synthesis of the *Calophyllum* Coumarins, *Tetrahedron Letters*, 1994, 35, 5363-5366 is directed to synthesis of various coumarins and characterization thereof.

This is the replacement sheet

Date: 28 FEB 1997

AMENDED SHEET

WHAT IS CLAIMED IS:

1. A method for the preparation of ($\pm$)-calanolide A comprising the steps of:

(a) reacting 5,7-dihydroxy-8-propionyl-4-propylcoumarin with 4,4-dimethoxy-2-methylbutan-2-ol so as to produce 5-hydroxy-2,2-dimethyl-6-propionyl-10-propyl-2H,8H-benzo[1,2-b:3,4-b']-dipyrans-8-one;

(b) reacting 5-hydroxy-2,2-dimethyl-6-propionyl-10-propyl-2H,8H-benzo[1,2-b:3,4-b']-dipyrans-8-one with acetaldehyde diethyl acetal in the presence of an acid catalyst to form 12-oxocalanolide A; and

(c) reducing 12-oxocalanolide A so as to form ($\pm$)-calanolide A.

2. The method of claim 1, wherein the acid catalyst comprises sulfuric acid, trifluoroacetic acid, or methanesulfonic acid.

3. The method of claim 1, wherein step (c) is performed with a reducing agent comprising sodium borohydride, zinc borohydride, borane, or selectrides in the presence of a metal additive comprising $\text{CeCl}_3(\text{H}_2\text{O})_7$, ZnCl_2 , AlCl_3 , TiCl_4 , SnCl_4 , or LnCl_3 , or their mixture with triphenylphosphine oxide.

4. The method of claim 3, wherein step (c) is performed with sodium borohydride and $\text{CeCl}_3(\text{H}_2\text{O})_7$.

5. The method of claim 1, wherein step (a) 5,7-dihydroxy-8-propionyl-4-propylcoumarin is prepared by

(a) condensing ethyl butyrylacetate and phloroglucinol in the presence of an acid catalyst to form 5,7-dihydroxy-4-propylcoumarin; and

(b) acylating 5,7-dihydroxy-4-propylcoumarin with propionyl chloride in the presence of a Lewis acid to form 5,7-dihydroxy-8-propionyl-4-propylcoumarin.



This is the replacement sheet **AMENDED SHEET**

Date: 28 FEB 1997

6. The method of claim 5, wherein step (a) acid catalyst comprises sulfuric acid, trifluoroacetic acid, methanesulfonic acid, or trifluoromethanesulfonic acid.


7. The method of claim 5, wherein step (b) Lewis acid comprises AlCl_3 , ZnCl_2 , TiCl_4 , BF_3 , POCl_3 , or SnCl_4 .

8. 5-Hydroxy-2,2-dimethyl-6-propionyl-10-propyl-2H,8H-benzo[1,2-b:3,4-b']-dipyran-8-one.


9. 5,7-Dihydroxy-8-propionyl-4-propylcoumarin.

10. A method for the preparation of ($\pm$)-calanolide A comprising steps of:

(a) reacting chromene 4 with paraldehyde in the presence of an acid catalyst



to form chromanone 7;



This is the replacement sheet

Date: 28 FEB 1997


AMENDED SHEET

(b) reducing chromanone 7 so as to form (±)-calanolide A.

11. The method of claim 10, wherein step (a) acid catalyst comprises trifluoroacetic acid, trifluoromethanesulfonic acid, methanesulfonic acid, or pyridinium salts thereof.

12. The method of claim 10, wherein step (b) is performed with a reducing agent comprising sodium borohydride, zinc borohydride, borane or selectrides in the presence of a metal additive comprising $\text{CeCl}_3 \cdot (\text{H}_2\text{O})_7$, ZnCl_2 , AlCl_3 , TiCl_4 , SnCl_3 , LnCl_3 , or mixtures thereof with triphenylphosphine oxide.

13. A method for the preparation of chromene 4



comprising the steps of:

(a) acylating 5,7-dihydroxy-4-propylcoumarin with propionic anhydride in the presence of a Lewis acid so as to produce 5,7-dihydroxy-8-propionyl-4-propylcoumarin;

(b) reacting said 5,7-dihydroxy-8-propionyl-4-propylcoumarin with 4,4-dimethoxy-2-methylbutan-2-ol in the presence of a base so as to produce chromene 4.

14. The method of claim 13, wherein step (a) Lewis acid comprises AlCl_3 , ZnCl_2 , TiCl_4 , BF_3 , POCl_3 , or SnCl_4 .

This is the replacement sheet




Date: 28 FEB 1997

AMENDED SHEET


15. The method of claim 13, wherein step (b) base comprises pyridine, 4-dimethylaminopyridine, triethylamine, N,N-diethylaniline, 1,5-diazabicyclo[4,3,0]non-5-ene (DBN), 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU), sodium carbonate or sodium bicarbonate.

16. The method of claim 13, wherein step (b) is conducted in the presence of a solvent comprising N,N-dimethylformamide (DMF), toluene, 1,2-dichloroethane and THF.

17. A method for preparation of chromanone 7



comprising cyclizing of aldol product 7b



in the presence of an acid or in the presence of an azo compound and a phosphorus derivative.



This is the replacement sheet

AMENDED SHEET


Date: 28 FEB 1997

18. The method of claim 17, wherein the acid comprises sulfuric acid, hydrochloric acid, trifluoroacetic acid, methanesulfonic acid, trifluoromethanesulfonic acid, *p*-tosylic acid, acetic acid or mixtures thereof.

19 The method of claim 17, wherein the azo compound comprises diethyl azodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD), dibutyl azodicarboxylate (DBAD), dipiperidinoazodicarboxoamide, bis(*N*⁴-methylpiperazin-1-yl)azodicarboxamide, dimorpholinoazodicarboxamide, or *N,N,N',N'*-tetramethylazodicarboxomide (TMAD).

20. The method of claim 17, wherein the phosphorous derivative comprises triphenylphosphine, tri-*n*-butylphosphine, triethylphosphine, trimethylphosphine and tris(dimethylamino)phosphine.

21. The method of claim 17, wherein said aldol product 7b is prepared by reacting chromene 4



with acetaldehyde in the presence of a base or metal complex.



This is the replacement sheet

Date:

28 FEB 1997


AMENDED SHEET

22. The method of claim 21, wherein the base comprises a metal hydroxide, a metal alkoxide, a metal hydride, a metal amide, an amine, or LiHMDS.

23. The method of claim 21, wherein the metal complex comprises TiCl_4 , $(i\text{-PrO})_3\text{TiCl}$, $(i\text{-PrO})_4\text{Ti}$, PhBCl_2 , $(n\text{-Bu})_2\text{BCl}$, BF_3 , $(n\text{-Bu})_3\text{SnCl}$, SnCl_4 , ZnCl_2 , MgBr_2 , or Et_2AlCl .


24. The method of claim 23, further comprising a chiral auxiliary comprising 1,1'-binaphthol, norephedrine sulfonate, camphanediol, diacetone glucose or dialkyl tartrate.

25. A method of preparation of chromanone 7



7

comprising treating *cis*-chromanone 7a



7a

with a base so as to form chromanone 7.

This is the replacement sheet

Date: 28 FEB 1997

AMENDED SHEET



* C L M S *

26. The method of claim 25, wherein the base comprises a metal hydroxide, a metal alkoxide, a metal hydride, a metal amide, an amine, or LiHMDS.

27. A method of chiral resolution of ($\pm$)-calanolide A into its optically active forms, (+)-calanolide A and (-)-calanolide A, comprising passing ($\pm$)-calanolide A through a column comprising a chiral solid phase using an organic solvent system as a mobile phase.

28. The method of claim 27, wherein said chiral solid phase comprises amylose carbamate, D-phenylglycine, L-phenylglycine, D-leucine, L-leucine, D-naphthylalanine, L-naphthylalanine, or L-naphthylleucine.

29. The method of claim 27, wherein the column comprises an HPLC column.

30. The method of claim 27, wherein the chiral solid phase comprises amylose carbamate.

31. The method of claim 27, wherein a mobile phase comprising hexane, heptane, cyclohexane, ethyl acetate, methanol, ethanol, isopropanol or mixtures thereof.

32. The method of claim 31, wherein the mobile phase comprises a mixture of hexane and ethyl acetate.

33. A method for the chiral resolution ($\pm$)-calanolide A comprising the steps of:

(a) contacting ($\pm$)-calanolide A with an enzyme and an acylating agent to as to form a diastereomeric mixture of esterified and unesterified calanolide A; and

(b) separating out the esterified calanolide A from the mixture.

This is the replacement sheet

Date: 28 FEB 1997

AMENDED SHEET




34. The method of claim 33, wherein the enzyme comprises lipase CC (Candida Cyldracea), lipase AK (Candida Cyldracea), lipase AY (Candida Cyldracea), lipase PS (Pseudomonas Species), lipase AP (aspergillus niger), lipase N (Rhizopus nieveus), lipase FAP (Rhizopus nieveus), lipase PP (Porcine Pancrease), Pig (porcine) Liver Esterase (PLE), Pig Liver Acetone Powder (PLAP), or subtilisin.

35. The method of claim 34, wherein the enzyme is immobilized on cellite, molecular sieves, or ion exchange resin.

36. The method of claim 33, wherein the acylating agent comprises vinyl acetate, vinyl propionate, vinyl butyrate, acetic anhydride, propionic anhydride, phthalic anhydride, acetic acid, propionic acid, hexanoic acid or octanoic acid.

37. 5-Hydroxy-2,2-dimethyl-6-(2-methyl-3-hydroxybutyro)-10-propyl-2H,8H-benzo[1,2-b:3,4-b']dipyrans-8-one



76.




This is the replacement sheet

AMENDED SHEET

Date: 28 FEB 1997

38. 10,11-*cis*-Dihydro-6,6,10,11,tetramethyl-4-propyl-2H,6H,12H-benzo[1,2-b:3,4-b':5,6-b'']-tripyran-2,12-dione



7a.

39. (-)-Calanolide A.

40. An antiviral composition which comprises an antiviral effective, non-toxic amount of ($\pm$)-calanolide A or (-)-calanolide A and a pharmaceutically acceptable carrier.

41. The composition of claim 40, which further comprises an antiviral effective amount of at least one additional antiviral compound.

42. The composition of claim 41, wherein said antiviral compound comprises AZT or DDC.

43. A method of preventing or treating a viral infection in a mammal comprises administering to a mammal an antiviral effective, non-toxic amount of ($\pm$)-calanolide A or (-)-calanolide A.

44. The method of claim 43, which further comprises co-administering an antiviral effective amount of at least one additional antiviral compound.



This is the replacement sheet

Date: 28 Feb 1997

AMENDED SHEET

45. The method of claim 44, wherein said antiviral compound comprises AZT or DDC.

46. The method of claim 41, wherein said viral infection is by retrovirus.

47. The method of claim 46, wherein said retrovirus is a human immunodeficiency virus (HIV).

48. The method of claim 43, wherein the mammal is a human.



This is the replacement sheet

AMENDED SHEET


Date: 28 FEB 1997

U/24

FIG. 1A

SUMMARY GRAPH

DDC vs. HIV



This is the replacement sheet


AMENDED SHEET

Date: 28 FEB 1997

2/24

FIG. 1B

**SUMMARY GRAPH
AZT vs HIV**



This is the replacement sheet


AMENDED SHEET

Date: 28 FEB 1997

3/24

FIG. 1C

**SUMMARY GRAPH
(-) CALANOLIDE A vs HIV**



This is the replacement sheet


AMENDED SHEET

Date: 28 FEB 1997

4/24

FIG. 1D


SUMMARY GRAPH
(+) CALANOLIDE A vs. HIV



5/24

FIG. 1E

**SUMMARY GRAPH
RACEMIC CALANOLIDE A vs. HIV**



AMENDED SHEET.

This is the replacement sheet


Date: 28 FEB 1997

6/24

FIG. 2A

SUMMARY GRAPH

DDC vs. HIV




7/24

FIG. 2B

SUMMARY GRAPH

AZT vs. HIV



AMENDED SHEET


This is the replacement sheet

Date: 28 FEB 1997

8/24

FIG. 2C

SUMMARY GRAPH
(-) CALANOLIDE A vs. HIV



AMENDED SHEET


This is the replacement sheet

Date: 28 FEB 1997

9/24

FIG. 2D


SUMMARY GRAPH
(+) CALANOLIDE A vs. HIV



10/24

FIG. 2E

**SUMMARY GRAPH
RACEMIC CALANOLIDE A vs. HIV**



AMENDED SHEET

This is the replacement sheet


Date: 28 FEB 1997

11/24

FIG. 3A

SUMMARY GRAPH

DDC vs. HIV



AMENDED SHEET

This is the replacement sheet


Date: 28 FEB 1997

FIG. 3B

12/24

SUMMARY GRAPH

AZT vs. HIV




13/24

FIG. 3C

SUMMARY GRAPH


(-) CALANOLIDE A vs. HIV



14/24

FIG. 3D

SUMMARY GRAPH
(+) CALANOLIDE A vs HIV



AMENDED SHEET


This is the replacement sheet

Date: 28 FEB 1997

15/24

FIG. 3E

**SUMMARY GRAPH
RACEMIC CALANOLIDE A vs. HIV**



AMENDED SHEET

This is the replacement sheet


Date: 28 FEB 1997

16/24

FIG. 4A

SUMMARY GRAPH

AZT vs. HIV



AMENDED SHEET

This is the replacement sheet

Date: 28 FEB 1997

17/24

FIG. 4B

SUMMARY GRAPH

DDC vs. HIV





FIG. 4C

18/24

**SUMMARY GRAPH
RACEMIC CALANOLIDE A vs. HIV**



AMENDED SHEET

This is the replacement sheet.


Date: 28 FEB 1997

19/24

FIG. 4D

SUMMARY GRAPH

(+) CALANOLIDE A vs. HIV




20/24

FIG. 5A

SUMMARY GRAPH

AZT vs. HIV



AMENDED SHEET

This is the replacement sheet

Date: 28 FEB 1997

AMENDED SHEET

Date: 28 FEB 1997